@article {pmid34047035,
year = {2021},
author = {McCaughan, G and Di Ciaccio, P and Ananda-Rajah, M and Gilroy, N and MacIntyre, R and Teh, B and Weinkove, R and Curnow, J and Szer, J and Enjeti, AK and Ross, DM and Mulligan, S and Trotman, J and Dickinson, M and Quach, H and Choi, P and Polizzotto, MN and Tam, CS and Ho, PJ and Ku, M and Gregory, G and Gangatharan, S and Hapgood, G and Cochrane, T and Cheah, C and Gibbs, S and Wei, A and Johnston, A and Greenwood, M and Prince, HM and Latimer, M and Berkahn, L and Wight, J and Armytage, T and Hamad, N},
title = {COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.},
journal = {Internal medicine journal},
volume = {51},
number = {5},
pages = {763-768},
pmid = {34047035},
issn = {1445-5994},
mesh = {Australia/epidemiology ; *COVID-19 ; COVID-19 Vaccines ; Consensus ; *Hematology ; Humans ; New Zealand/epidemiology ; Prospective Studies ; SARS-CoV-2 ; Vaccination ; },
abstract = {Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.},
}

Australia/epidemiology
*COVID-19
COVID-19 Vaccines
Consensus
*Hematology
Humans
New Zealand/epidemiology
Prospective Studies
SARS-CoV-2
Vaccination

@article {pmid34030157,
year = {2021},
author = {Exten, C and Pinto, CN and Gaynor, AM and Meyerson, B and Griner, SB and Van Der Pol, B and , },
title = {Direct-to-Consumer Sexually Transmitted Infection Testing Services: A Position Statement from the American Sexually Transmitted Diseases Association.},
journal = {Sexually transmitted diseases},
volume = {48},
number = {11},
pages = {e155-e159},
pmid = {34030157},
issn = {1537-4521},
mesh = {*COVID-19 ; Humans ; Pandemics ; SARS-CoV-2 ; *Sexually Transmitted Diseases/diagnosis/epidemiology ; Specimen Handling ; United States/epidemiology ; },
abstract = {Direct-to-consumer test services have gained popularity for sexually transmitted infections in recent years, with substantially increased use as a result of the SARS-CoV-2 (CoVID-19) global pandemic. This method of access has been variously known as "self-testing," "home testing," and "direct access testing." Although these online services may be offered through different mechanisms, here we focus on those that are consumer-driven and require self-collected samples, and sample shipment to a centralized laboratory without involvement of health care providers and/or local health departments. We provide the American Sexually Transmitted Diseases Association's position on utilization of these services and recommendations for both consumers and health care providers.},
}

*COVID-19
Humans
Pandemics
SARS-CoV-2
*Sexually Transmitted Diseases/diagnosis/epidemiology
Specimen Handling
United States/epidemiology

@article {pmid33976449,
year = {2020},
author = {Awuku, YA and Jibril, AT and Bockarie, AS and Duah, A and Tachi, K and Agyei-Nkansah, A and Afihene, MY},
title = {Gastroenterology practice in the COVID-19 era: Ghana Association for the Study of Liver and Digestive Diseases (GASLIDD) position statement.},
journal = {Ghana medical journal},
volume = {54},
number = {4 Suppl},
pages = {104-106},
pmid = {33976449},
issn = {2616-163X},
mesh = {COVID-19/*prevention & control ; Endoscopy, Gastrointestinal/*standards ; Gastroenterology/*standards ; Ghana ; Humans ; Infection Control/*standards ; *Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {UNLABELLED: The COVID-19 pandemic has impacted healthcare negatively across the globe. The practice of gastroenterology has been affected especially gastrointestinal (GI) endoscopy which is considered high risk for transmission of the virus. As a community of practitioners there is the need to share information and make evidence-based statements to guide GI practice in Ghana. This GASLIDD position statement based on the growing and rapidly evolving body of knowledge is to provide up to date information on the COVID-19 disease and guidance for the practice of gastroenterology in Ghana and beyond. It is to help the GI community of practice to maintain the highest level of health delivery and safety for our patients, staff, community and GI practitioners.

FUNDING: Self-funded.},
}

COVID-19/*prevention & control
Endoscopy, Gastrointestinal/*standards
Gastroenterology/*standards
Ghana
Humans
Infection Control/*standards
*Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical

@article {pmid33960979,
year = {2021},
author = {Indolfi, C and Barillà, F and Basso, C and Ciccone, MM and Curcio, A and Mancone, M and Mercuro, G and Muscoli, S and Nodari, S and Pedrinelli, R and Romeo, F and Sinagra, G and Filardi, PP},
title = {[Position paper of the Italian Society of Cardiology (SIC) on COVID-19 vaccine priority in patients with cardiovascular diseases].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {5},
pages = {363-375},
doi = {10.1714/3592.35745},
pmid = {33960979},
issn = {1972-6481},
mesh = {Age Factors ; Animals ; COVID-19/epidemiology/mortality/*prevention & control ; COVID-19 Vaccines/*administration & dosage ; Cardiology ; Cardiovascular Diseases/*complications ; *Consensus ; Coronary Disease/complications ; Disease Vectors ; Heart Failure/complications ; Heart Transplantation ; Heart Valve Diseases/complications ; Humans ; Hypertension, Pulmonary/complications ; Italy/epidemiology ; Prognosis ; Renal Insufficiency/complications ; SARS-CoV-2/immunology ; Societies, Medical ; Vaccines, Synthetic/administration & dosage ; mRNA Vaccines ; },
abstract = {In over a year, the COVID-19 pandemic caused 2.69 million deaths and 122 million infections. Social isolation and distancing measures have been the only prevention available for months. Scientific research has done a great deal of work, developing in a few months safe and effective vaccines against COVID-19. In the European Union, nowadays, four vaccines have been authorized for use: Pfizer-BioNTech, Moderna, ChAdOx1 (AstraZeneca/Oxford), Janssen (Johnson & Johnson), and three others are currently under rolling review.Vaccine allocation policy is crucial to optimize the advantage of treatment preferring people with the highest risk of contagion. These days the priority in the vaccination program is of particular importance since it has become clear that the number of vaccines is not sufficient for the entire Italian population in the short term. Cardiovascular diseases are frequently associated with severe COVID-19 infections, leading to the worst prognosis. The elderly population suffering from cardiovascular diseases is, therefore, to be considered a particularly vulnerable population. However, age cannot be considered the only discriminating factor because in the young-adult population suffering from severe forms of heart disease, the prognosis, if affected by COVID-19, is particularly ominous and these patients should have priority access to the vaccination program. The aim of this position paper is to establish a consensus on a priority in the vaccination of COVID-19 among subjects suffering from different cardiovascular diseases.},
}

Age Factors
Animals
COVID-19/epidemiology/mortality/*prevention & control
COVID-19 Vaccines/*administration & dosage
Cardiology
Cardiovascular Diseases/*complications
*Consensus
Coronary Disease/complications
Disease Vectors
Heart Failure/complications
Heart Transplantation
Heart Valve Diseases/complications
Humans
Hypertension, Pulmonary/complications
Italy/epidemiology
Prognosis
Renal Insufficiency/complications
SARS-CoV-2/immunology
Societies, Medical
Vaccines, Synthetic/administration & dosage
mRNA Vaccines

@article {pmid33941488,
year = {2021},
author = {Russo, FP and Piano, S and Bruno, R and Burra, P and Puoti, M and Masarone, M and Montagnese, S and Ponziani, FR and Petta, S and Aghemo, A and , },
title = {Italian association for the study of the liver position statement on SARS-CoV2 vaccination.},
journal = {Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
volume = {53},
number = {6},
pages = {677-681},
pmid = {33941488},
issn = {1878-3562},
mesh = {*COVID-19/epidemiology/prevention & control ; *COVID-19 Vaccines/classification/pharmacology ; Humans ; *Immunization Programs/methods/organization & administration ; Immunosuppressive Agents/therapeutic use ; Italy/epidemiology ; *Liver Diseases/immunology/therapy ; Liver Transplantation ; Patient Safety ; Patient Selection ; Risk Adjustment/*methods ; Risk Assessment ; SARS-CoV-2/immunology ; Transplant Recipients ; Treatment Outcome ; },
abstract = {The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver disease, a possible priority for vaccination for this category of patients.},
}

*COVID-19/epidemiology/prevention & control
*COVID-19 Vaccines/classification/pharmacology
Humans
*Immunization Programs/methods/organization & administration
Immunosuppressive Agents/therapeutic use
Italy/epidemiology
*Liver Diseases/immunology/therapy
Liver Transplantation
Patient Safety
Patient Selection
Risk Adjustment/*methods
Risk Assessment
SARS-CoV-2/immunology
Transplant Recipients
Treatment Outcome

@article {pmid33909805,
year = {2021},
author = {Queiroz, NSF and Teixeira, FV and Freire, CCF and Motta, MP and Vasconcellos, MAM and Chebli, LA and Saad-Hossne, R and , },
title = {BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION.},
journal = {Arquivos de gastroenterologia},
volume = {58},
number = {1},
pages = {1-4},
doi = {10.1590/S0004-2803.202100000-02},
pmid = {33909805},
issn = {1678-4219},
mesh = {Brazil ; *COVID-19 ; COVID-19 Vaccines ; Humans ; *Inflammatory Bowel Diseases ; Pandemics ; RNA, Viral ; SARS-CoV-2 ; Vaccination ; },
abstract = {Mass vaccination offers the best strategy to fight against COVID-19 pandemic, and SARS-CoV2 vaccines are being approved in several countries for emergency use. In Brazil, vaccine approval is expected in the next few days, however potential concerns exist regarding vaccine recommendations for specific populations, such as patients with inflammatory bowel disease (IBD). To address these questions, the Brazilian IBD Study Group (GEDIIB) provides this practical advice with key recommendations about the COVID-19 vaccines in IBD population.},
}

Brazil
*COVID-19
COVID-19 Vaccines
Humans
*Inflammatory Bowel Diseases
Pandemics
RNA, Viral
SARS-CoV-2
Vaccination

@article {pmid33861837,
year = {2020},
author = {Álvarez Z, P and Larios G, G and Toro R, L and Acevedo A, V and Arancibia G, F and Cárdenas M, L and Fernández C, C},
title = {[Recommendation for the recognition, management and follow up of cardiovascular compromise in patients with Pediatric Multisystemic Inflammatory Syndrome associated with COVID-19 (PIMS-CT). Position statement of Chilean Scientific Societies].},
journal = {Revista chilena de pediatria},
volume = {91},
number = {6},
pages = {982-990},
doi = {10.32641/rchped.vi91i6.3215},
pmid = {33861837},
issn = {0717-6228},
mesh = {Biomarkers/metabolism ; COVID-19/diagnosis/physiopathology/*therapy ; Cardiovascular Diseases/diagnosis/therapy/*virology ; Child ; Chile ; Humans ; Mucocutaneous Lymph Node Syndrome/therapy/virology ; Patient Care Team/organization & administration ; Shock/therapy/virology ; Systemic Inflammatory Response Syndrome/diagnosis/physiopathology/*therapy ; },
abstract = {Since the onset of the SARS-CoV-2 pandemic, the pediatric population has been less affected by the disease both in frequency and severity. However, since April cases of variable presentation and severity characterized by inflammatory phenomena that affect multiple organs have been reported, a condition called Multisystem Inflammatory Syndrome in Children (MIS-C). The literature has reported frequent cardiac involvement, up to 80%. This is characterized by myocardial injury with a significant increase of biomarkers such as serum troponins I and T, BNP, or NT-ProBNP coupled with varying degrees of ventricular dysfunction, pericarditis, valvulitis, and arrhythmias. Coronary compromise has also been described, which can occur in up to 23% of cases, and ranges from dila tations to aneurysms. Inpatient and outpatient cardiology follow-up has been systematized based on the clinical phenotypes such as myocardial injury (myocarditis, valvulitis, pericarditis), shock (usua lly vasoplegic), Kawasaki disease-type manifestations, and those MIS-C that do not comply with the clinic of the previous three. This last group represents the main challenge in the short-, medium- and long-term follow-up, therefore, it is necessary a multidisciplinary team for managing these patients. Considering the high frequency of cardiac compromise in MIS-C, and the importance of reaching a consensus regarding its management and follow-up, we present these recommendations according to the current state of knowledge regarding this recently described pathology.},
}

Biomarkers/metabolism
COVID-19/diagnosis/physiopathology/*therapy
Cardiovascular Diseases/diagnosis/therapy/*virology
Child
Chile
Humans
Mucocutaneous Lymph Node Syndrome/therapy/virology
Patient Care Team/organization & administration
Shock/therapy/virology
Systemic Inflammatory Response Syndrome/diagnosis/physiopathology/*therapy

@article {pmid33839767,
year = {2021},
author = {Badimon, L and Robinson, EL and Jusic, A and Carpusca, I and deWindt, LJ and Emanueli, C and Ferdinandy, P and Gu, W and Gyöngyösi, M and Hackl, M and Karaduzovic-Hadziabdic, K and Lustrek, M and Martelli, F and Nham, E and Potočnjak, I and Satagopam, V and Schneider, R and Thum, T and Devaux, Y},
title = {Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129.},
journal = {Cardiovascular research},
volume = {117},
number = {8},
pages = {1823-1840},
pmid = {33839767},
issn = {1755-3245},
support = {CH/15/1/31199/BHF_/British Heart Foundation/United Kingdom ; RG/20/9/35101/BHF_/British Heart Foundation/United Kingdom ; },
mesh = {Artificial Intelligence/*economics ; Biomarkers/*analysis ; COVID-19/*diagnosis ; Cardiovascular Diseases/diagnosis/genetics ; Cardiovascular System/virology ; Humans ; Quality of Life ; RNA/*genetics ; SARS-CoV-2/pathogenicity ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has been as unprecedented as unexpected, affecting more than 105 million people worldwide as of 8 February 2020 and causing more than 2.3 million deaths according to the World Health Organization (WHO). Not only affecting the lungs but also provoking acute respiratory distress, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to infect multiple cell types including cardiac and vascular cells. Hence a significant proportion of infected patients develop cardiac events, such as arrhythmias and heart failure. Patients with cardiovascular comorbidities are at highest risk of cardiac death. To face the pandemic and limit its burden, health authorities have launched several fast-track calls for research projects aiming to develop rapid strategies to combat the disease, as well as longer-term projects to prepare for the future. Biomarkers have the possibility to aid in clinical decision-making and tailoring healthcare in order to improve patient quality of life. The biomarker potential of circulating RNAs has been recognized in several disease conditions, including cardiovascular disease. RNA biomarkers may be useful in the current COVID-19 situation. The discovery, validation, and marketing of novel biomarkers, including RNA biomarkers, require multi-centre studies by large and interdisciplinary collaborative networks, involving both the academia and the industry. Here, members of the EU-CardioRNA COST Action CA17129 summarize the current knowledge about the strain that COVID-19 places on the cardiovascular system and discuss how RNA biomarkers can aid to limit this burden. They present the benefits and challenges of the discovery of novel RNA biomarkers, the need for networking efforts, and the added value of artificial intelligence to achieve reliable advances.},
}

Artificial Intelligence/*economics
Biomarkers/*analysis
COVID-19/*diagnosis
Cardiovascular Diseases/diagnosis/genetics
Cardiovascular System/virology
Humans
Quality of Life
RNA/*genetics
SARS-CoV-2/pathogenicity

@article {pmid33820898,
year = {2021},
author = {Rodrigues, AM and Romeu, JC and Canas da Silva, J and Tavares-Costa, J and Faustino, A and Vaz, C and Pereira da Silva, JA and Canhão, H},
title = {Osteoporosis management during the COVID-19 pandemic - Position paper.},
journal = {Acta reumatologica portuguesa},
volume = {46},
number = {1},
pages = {55-57},
pmid = {33820898},
issn = {2184-8777},
mesh = {*COVID-19 ; Humans ; Osteoporosis/*therapy ; },
abstract = {COVID-19 pandemic significantly increased the already large number of victims of osteoporosis in Portugal. Osteoporosis outpatient clinics were either closed or had limited presential appointments. Many hospitals reduced orthopaedic services to make space for patients with COVID-19. In addition, the volunteer or forced sedentarism, as imposed by the pandemic, increased the risk of falls and fractures drastically. It urges to intensify the current efforts to improve the management of bone health and to prioritize fragility fracture care and prevention. This paper addresses the challenges in osteoporosis management during the COVID-19 pandemic and provides guidance on osteoporosis management. This position paper is a joint initiative of several health professionals and patients dedicated to osteoporosis.},
}

*COVID-19
Humans
Osteoporosis/*therapy

@article {pmid33780557,
year = {2021},
author = {Arenbergerova, M and Lallas, A and Nagore, E and Rudnicka, L and Forsea, AM and Pasek, M and Meier, F and Peris, K and Olah, J and Posch, C},
title = {Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {35},
number = {7},
pages = {e427-e428},
pmid = {33780557},
issn = {1468-3083},
support = {PROGRES Q28//Charles University, Prague, Czech Republic/ ; },
mesh = {*COVID-19 ; Humans ; *Melanoma/therapy ; SARS-CoV-2 ; *Skin Neoplasms/therapy ; },
}

*COVID-19
Humans
*Melanoma/therapy
SARS-CoV-2
*Skin Neoplasms/therapy

@article {pmid33752263,
year = {2021},
author = {Ring, J and Worm, M and Wollenberg, A and Thyssen, JP and Jakob, T and Klimek, L and Bangert, C and Barbarot, S and Bieber, T and de Bruin-Weller, MS and Chernyshov, PV and Christen-Zaech, S and Cork, M and Darsow, U and Flohr, C and Fölster-Holst, R and Gelmetti, C and Gieler, U and Gutermuth, J and Heratizadeh, A and Hijnen, DJ and von Kobyletzki, LB and Kunz, B and Paul, C and De Raeve, L and Seneschal, J and Simon, D and Spuls, PI and Stalder, JF and Svensson, A and Szalai, Z and Taieb, A and Torrelo, A and Trzeciak, M and Vestergaard, C and Werfel, T and Weidinger, S and Deleuran, M},
title = {Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {35},
number = {6},
pages = {e362-e365},
pmid = {33752263},
issn = {1468-3083},
mesh = {*Anaphylaxis ; *COVID-19 ; COVID-19 Vaccines ; *Dermatitis, Atopic/prevention & control ; Humans ; SARS-CoV-2 ; *Vaccines ; },
}

*Anaphylaxis
*COVID-19
COVID-19 Vaccines
*Dermatitis, Atopic/prevention & control
Humans
SARS-CoV-2
*Vaccines

@article {pmid33642133,
year = {2021},
author = {Tarazona-Santabalbina, FJ and Cuadra, L and Cancio, JM and Carbonell, FR and Garrote, JMP and Casas-Herrero, Á and Martínez-Velilla, N and Serra-Rexach, JA and Formiga, F},
title = {VitaminD supplementation for the prevention and treatment of COVID-19: a position statement from the Spanish Society of Geriatrics and Gerontology.},
journal = {Revista espanola de geriatria y gerontologia},
volume = {56},
number = {3},
pages = {177-182},
pmid = {33642133},
issn = {1578-1747},
mesh = {Aged ; COVID-19/complications/immunology/prevention & control/*therapy ; *Cytokine Release Syndrome/prevention & control ; *Dietary Supplements ; *Geriatrics ; Humans ; Receptors, Calcitriol/metabolism ; Societies, Medical ; Spain ; Vitamin D/*administration & dosage/immunology ; Vitamin D Deficiency/complications/*therapy ; Vitamins/*administration & dosage/immunology ; },
abstract = {The coronavirus disease 2019 (COVID-19) produces severe respiratory symptoms such as bilateral pneumonia associated to a high morbidity and mortality, especially in patients of advanced age. Vitamin D deficiency has been reported in several chronic conditions associated with increased inflammation and dysregulation of the immune system. Vitamin D in modulates immune function too. Vitamin D receptor (VDR) is expressed by most immune cells, including B and T lymphocytes, monocytes, macrophages, and dendritic cells and the signalling of vitamin D and VDR together has an anti-inflammatory effect. Some studies have reported that vitamin D treatment could be useful for the prevention and treatment of COVID-19 because vitamin D plays an important role as a modulator of immunocompetence. Over the last few months, some studies have hypothesized the possible beneficial effect of vitamin D supplementation in patients with COVID-19 in order to improve the immune balance and prevent the hyperinflammatory cytokine storm. Some preliminary studies have already shown promising results with vitamin D supplementation in hospitalized COVID-19 patients. Vitamin D should be administered daily until adequate levels are achieved due to vitamin D behaves as a negative acute phase reactant (APR). Despite the lack of evidence on specific doses of vitamin D to treat COVID-19 in older adults, authors consider it is necessary to standardize the use in clinical practice. These recommendations advice supplement vitamin D in a protocoled fashion based on expert opinions, level of evidence 5.},
}

Aged
COVID-19/complications/immunology/prevention & control/*therapy
*Cytokine Release Syndrome/prevention & control
*Dietary Supplements
*Geriatrics
Humans
Receptors, Calcitriol/metabolism
Societies, Medical
Spain
Vitamin D/*administration & dosage/immunology
Vitamin D Deficiency/complications/*therapy
Vitamins/*administration & dosage/immunology

@article {pmid33533553,
year = {2021},
author = {Beecker, J and Papp, KA and Dutz, J and Vender, RB and Gniadecki, R and Cooper, C and Gisondi, P and Gooderham, M and Hong, CH and Kirchhof, MG and Lynde, CW and Maari, C and Poulin, Y and Puig, L},
title = {Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {35},
number = {4},
pages = {797-806},
pmid = {33533553},
issn = {1468-3083},
mesh = {COVID-19/complications/*epidemiology/therapy ; Dermatitis/*therapy ; Humans ; *Immunotherapy ; Practice Patterns, Physicians' ; Risk Assessment ; },
abstract = {Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel RNA virus that was declared a global pandemic on 11 March 2020. The efficiency of infection with SARS-CoV-2 is reflected by its rapid global spread. The SARS-CoV-2 pandemic has implications for patients with inflammatory skin diseases on systemic immunotherapy who may be at increased risk of infection or more severe infection. This position paper is a focused examination of current evidence considering the mechanisms of action of immunotherapeutic drugs in relation to immune response to SARS-CoV-2. We aim to provide practical guidance for dermatologists managing patients with inflammatory skin conditions on systemic therapies during the current pandemic and beyond. Considering the limited and rapidly evolving evidence, mechanisms of action of therapies, and current knowledge of SARS-CoV-2 infection, we propose that systemic immunotherapy can be continued, with special considerations for at risk patients or those presenting with symptoms.},
}

COVID-19/complications/*epidemiology/therapy
Dermatitis/*therapy
Humans
*Immunotherapy
Practice Patterns, Physicians'
Risk Assessment

@article {pmid33518409,
year = {2021},
author = {Zimmerman, E and Martins, NN and Verheijen, RHM and Mahmood, T},
title = {EBCOG position statement - Simulation-based training for obstetrics and gynaecology during the COVID-19 pandemic.},
journal = {European journal of obstetrics, gynecology, and reproductive biology},
volume = {258},
number = {},
pages = {457-458},
pmid = {33518409},
issn = {1872-7654},
mesh = {COVID-19/epidemiology ; Curriculum ; Female ; Gynecology/*education ; Humans ; Obstetrics/*education ; Pandemics ; Pregnancy ; SARS-CoV-2 ; Simulation Training/*standards ; },
abstract = {The specialty of Obstetrics and Gynaecology has been on the forefront of introducing simulation in post graduate education for the past two decades. Simulation training is known to enhance psychomotor skills and is considered an important step in the transition from classroom learning to clinical practice. Training on simulators allows trainees to acquire basic skills before getting involved in day to day care in real life situations. Clinical circumstances around the COVID 19 pandemic have highlighted the key importance of simulation training in delivering post graduate curriculum.},
}

COVID-19/epidemiology
Curriculum
Female
Gynecology/*education
Humans
Obstetrics/*education
Pandemics
Pregnancy
SARS-CoV-2
Simulation Training/*standards

@article {pmid33495916,
year = {2021},
author = {Torres-Naranjo, F and De la Peña-Rodríguez, P and López-Cervantes, RE and Morales-Torres, J and Morales-Vargas, J and Gutiérrez-Hermosillo, H and Guzmán-Rico, AC and González-Mendoza, RG and Rueda Plata, PN and Flores Castro, M and Celis Gonzalez, C and Espinosa Morales, R and Quintero Hernández, S and López-Taylor, JR},
title = {Joint position statement on management of patient with osteoporosis during COVID-19 contingency from the AMMOM, CONAMEGER, FELAEN, FEMECOG, FEMECOT, and ICAAFYD.},
journal = {Archives of osteoporosis},
volume = {16},
number = {1},
pages = {18},
pmid = {33495916},
issn = {1862-3514},
mesh = {Aged ; *COVID-19 ; Humans ; *Medicine ; *Orthopedics ; *Osteoporosis/epidemiology/therapy ; Pandemics ; SARS-CoV-2 ; *Traumatology ; },
abstract = {UNLABELLED: Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. This joint position statement of Latin American Medical Societies provides an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis.

BACKGROUND: Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. Characterized by high contagiousness, significative morbidity, and mortality in a segment of those infected, it has overwhelmed health services and forced to redirect resources to the emergency while impacting the attention of acute non-COVID-19 and many chronic conditions.

OBJECTIVE: The objective of this study is to provide an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis.

METHODS: A task force, of bone specialists with a wide range of disciplines in the field of osteoporosis and fragility fracture, was convened with the representation of several professional associations, namely, the Mexican Association of Bone and Mineral Metabolism (AMMOM), the National College of Geriatric Medicine (CONAMEGER), the Latin American Federation of Endocrinology (FELAEN), the Mexican Federation of Colleges of Obstetrics and Gynecology (FEMECOG), the Mexican Federation of Colleges of Orthopedics and Traumatology (FEMECOT), and the Institute of Applied Sciences for Physical Activity and Sports of the University of Guadalajara (ICAAFYD). Clinical evidence was collated, and an evidence report was rapidly generated and disseminated. After finding the gaps in the available evidence, a consensus opinion of experts was made. The resulting draft was reviewed and modified accordingly, in 4 rounds, by the participants.

RESULTS: The task force approved the initial guidance statements, with moderate and high consensus. These were combined, resulting in the final guidance statements on the (1) evaluation of fracture risk; (2) stratification of risk priorities; (3) indications of bone density scans and lab tests; (4) initiation and continuation of pharmacologic therapy; (5) interruptions of therapy; (6) treatment of patients with incident fracture; (7) physical therapy and fall prevention; and (8) nutritional interventions.

CONCLUSION: These guidance statements are provided to promote optimal care to patients at risk for osteoporosis and fracture, during the current COVID-19 pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document" and future updates are anticipated.},
}

Aged
*COVID-19
Humans
*Medicine
*Orthopedics
*Osteoporosis/epidemiology/therapy
Pandemics
SARS-CoV-2
*Traumatology

@article {pmid33419600,
year = {2021},
author = {White, SJ and Barello, S and Cao di San Marco, E and Colombo, C and Eeckman, E and Gilligan, C and Graffigna, G and Jirasevijinda, T and Mosconi, P and Mullan, J and Rehman, SU and Rubinelli, S and Vegni, E and Krystallidou, D},
title = {Critical observations on and suggested ways forward for healthcare communication during COVID-19: pEACH position paper.},
journal = {Patient education and counseling},
volume = {104},
number = {2},
pages = {217-222},
pmid = {33419600},
issn = {1873-5134},
mesh = {*COVID-19 ; *Health Communication ; Health Literacy ; Health Personnel/*psychology ; Health Promotion/*methods ; Humans ; Pandemics ; *Public Health Practice ; *SARS-CoV-2 ; *Telemedicine ; Uncertainty ; },
abstract = {OBJECTIVE: Communication in healthcare has influenced and been influenced by the COVID-19 pandemic. In this position paper, we share observations based on the latest available evidence and experiential knowledge that have emerged during the pandemic, with a specific focus on policy and practice.

METHODS: This is a position paper that presents observations relating to policy and practice in communication in healthcare related to COVID-19.

RESULTS: Through our critical observations as experts in the field of healthcare communication, we share our stance how healthcare communication has occured during the pandemic and suggest possible ways of improving policy and professional practice. We make recommendations for policy makers, healthcare providers, and communication experts while also highlighting areas that merit further investigation regarding healthcare communication in times of healthcare crises.

CONCLUSION: We have witnessed an upheaval of healthcare practice and the development of policy on-the-run. To ensure that policy and practice are evidence-based, person-centred, more inclusive and equitable, we advocate for critical reflection on this symbiotic relationship between COVID-19 and the central role of communication in healthcare.

PRACTICE IMPLICATIONS: This paper provides a summary of the key areas for development in communication in healthcare during COVID-19. It offers recommendations for improvement and a call to review policies and practice to build resilience and inclusive and equitable responsiveness in communication in healthcare.},
}

*COVID-19
*Health Communication
Health Literacy
Health Personnel/*psychology
Health Promotion/*methods
Humans
Pandemics
*Public Health Practice
*SARS-CoV-2
*Telemedicine
Uncertainty

@article {pmid33416050,
year = {2021},
author = {Chieffo, A and Tarantini, G and Naber, CK and Barbato, E and Roffi, M and Stefanini, GG and Buchanan, GL and Buszman, P and Moreno, R and Zawiślak, B and Cayla, G and Danenberg, H and Da Silveira, JAB and Nef, H and James, SK and Mauri Ferre, J and Voskuil, M and Witt, N and Windecker, S and Baumbach, A and Dudek, D},
title = {Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI).},
journal = {EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology},
volume = {16},
number = {14},
pages = {1177-1186},
pmid = {33416050},
issn = {1969-6213},
mesh = {*COVID-19 ; *Cardiovascular Surgical Procedures ; *Elective Surgical Procedures ; Humans ; Masks ; *Pandemics ; Personal Protective Equipment ; SARS-CoV-2 ; },
abstract = {The rearrangement of healthcare services required to face the coronavirus disease 2019 (COVID-19) pandemic led to a drastic reduction in elective cardiac invasive procedures. We are already facing a "second wave" of infections and we might be dealing during the next months with a "third wave" and subsequently new waves. Therefore, during the different waves of the COVID-19 pandemic we have to face the problems of how to perform elective cardiac invasive procedures in non-COVID patients and which patients/procedures should be prioritised. In this context, the interplay between the pandemic stage, the availability of healthcare resources and the priority of specific cardiac disorders is crucial. Clear pathways for "hot" or presumed "hot" patients and "cold" patients are mandatory in each hospital. Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test patients for SARS-CoV-2 infection before the interventional procedure, regardless of risk assessment for COVID-19. Pre-hospital testing should always be conducted in the presence of symptoms suggestive of SARS-CoV-2 infection. In cases of confirmed or suspected COVID-19 positive patients, full personal protective equipment using FFP 2/N95 masks, eye protection, gowning and gloves is indicated during cardiac interventions for healthcare workers. When patients have tested negative for COVID-19, medical masks may be sufficient. Indeed, individual patients should themselves wear medical masks during cardiac interventions and outpatient visits.},
}

*COVID-19
*Cardiovascular Surgical Procedures
*Elective Surgical Procedures
Humans
Masks
*Pandemics
Personal Protective Equipment
SARS-CoV-2

@article {pmid33378789,
year = {2021},
author = {Klimek, L and Jutel, M and Akdis, CA and Bousquet, J and Akdis, M and Torres, MJ and Agache, I and Canonica, GW and Del Giacco, S and O'Mahony, L and Shamji, MH and Schwarze, J and Untersmayr, E and Ring, J and Bedbrook, A and Worm, M and Zuberbier, T and Knol, E and Hoffmann-Sommergruber, K and Chivato, T},
title = {ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper.},
journal = {Allergy},
volume = {76},
number = {6},
pages = {1624-1628},
doi = {10.1111/all.14726},
pmid = {33378789},
issn = {1398-9995},
mesh = {BNT162 Vaccine ; *COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; *Vaccines/adverse effects ; },
abstract = {Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2, several severe anaphylaxis cases occured within the first few days of public vaccination. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and there are raising concerns that severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerge. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal, all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as this could have a significant impact on reaching the goal of population immunity. Healthcare practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognize and treat anaphylaxis properly with the ability to administer adrenaline. Further to vaccine administration, a mandatory observation period of at least 15 minutes should be followed for all individuals. The current data have not shown any higher risk for patients suffering from allergic rhinitis or asthma, and this message should be clearly stated by physicians to enable our patients to trust the vaccine. More than 30% of the population suffers from allergic diseases and the benefit of the vaccination clearly outweighs the risk of severe COVID-19 development.},
}

BNT162 Vaccine
*COVID-19
COVID-19 Vaccines
Humans
SARS-CoV-2
*Vaccines/adverse effects

@article {pmid33372938,
year = {2020},
author = {Corona, T and Castañón-González, JA and Clark-Peralta, P and García-Peña, C and Guevara-Guzmán, R and Domínguez-Cherit, G and Halabe-Cherem, J and López-Cervantes, M and Macias-Hernández, A and Rodríguez-Violante, M and Santillán-Doherty, P and Anda, GV and Guinzberg, AL},
title = {Position paper: Impact on medical and health personnel in the SARS-CoV-2 pandemic.},
journal = {Gaceta medica de Mexico},
volume = {156},
number = {5},
pages = {478-480},
doi = {10.24875/GMM.M20000432},
pmid = {33372938},
issn = {0016-3813},
mesh = {COVID-19/*prevention & control/*transmission ; *Health Personnel ; Humans ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Practice Guidelines as Topic ; },
}

COVID-19/*prevention & control/*transmission
*Health Personnel
Humans
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Practice Guidelines as Topic

@article {pmid33359375,
year = {2021},
author = {Mussini, C and Falcone, M and Nozza, S and Sagnelli, C and Parrella, R and Meschiari, M and Petrosillo, N and Mastroianni, C and Cascio, A and Iaria, C and Galli, M and Chirianni, A and Sagnelli, E and Iacobello, C and Di Perri, G and Mazzotta, F and Carosi, G and Tinelli, M and Grossi, P and Armignacco, O and Portelli, V and Andreoni, M and Tavio, M and , },
title = {Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT).},
journal = {Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
volume = {27},
number = {3},
pages = {389-395},
pmid = {33359375},
issn = {1469-0691},
mesh = {COVID-19/diagnosis/epidemiology/therapy ; Humans ; Italy/epidemiology ; *Practice Guidelines as Topic ; Randomized Controlled Trials as Topic ; SARS-CoV-2/isolation & purification ; Societies, Medical/*standards ; Standard of Care ; *COVID-19 Drug Treatment ; },
abstract = {SCOPE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting.

METHODS: The panel conducted a detailed review of the literature and eventual press releases from randomized clinical trials for each possible available treatment. Inductive PubMed search waws performed for publications relevant to the topic, including all clinical trials conducted. The result was a flowchart with treatment indications for patients with COVID-19.

IMPLICATIONS: After 6 months of a pandemic situation and before a possible second coronavirus wave descends on Europe, it is important to evaluate which drugs proved to be effective while also considering that results from many randomized clinical trials are still awaited. Indeed, among treatments for COVID-19, only glucocorticoids have resulted in an association with a significant decrease in mortality in published randomized controlled trials. New therapeutic strategies are urgently needed.},
}

COVID-19/diagnosis/epidemiology/therapy
Humans
Italy/epidemiology
*Practice Guidelines as Topic
Randomized Controlled Trials as Topic
SARS-CoV-2/isolation & purification
Societies, Medical/*standards
Standard of Care
*COVID-19 Drug Treatment

@article {pmid33313664,
year = {2021},
author = {Diller, GP and Gatzoulis, MA and Broberg, CS and Aboulhosn, J and Brida, M and Schwerzmann, M and Chessa, M and Kovacs, AH and Roos-Hesselink, J},
title = {Coronavirus disease 2019 in adults with congenital heart disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease.},
journal = {European heart journal},
volume = {42},
number = {19},
pages = {1858-1865},
pmid = {33313664},
issn = {1522-9645},
mesh = {Adult ; *COVID-19 ; *Cardiovascular Diseases ; *Heart Defects, Congenital/complications/epidemiology/therapy ; Humans ; Pandemics ; SARS-CoV-2 ; },
abstract = {We are witnessing an unparalleled pandemic caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) associated with coronavirus disease 2019 (COVID-19). Current data show that SARS-CoV-2 results in mild flu-like symptoms in the majority of healthy and young patients affected. Nevertheless, the severity of COVID-19 respiratory syndrome and the risk of adverse or catastrophic outcomes are increased in patients with pre-existing cardiovascular disease. Patients with adult congenital heart disease (ACHD)-by definition-have underlying cardiovascular disease. Many patients with ACHD are also afflicted with residual haemodynamic lesions such as valve dysfunction, diminished ventricular function, arrhythmias or cyanosis, have extracardiac comorbidities, and face additional challenges regarding pregnancy. Currently, there are emerging data of the effect of COVID-19 on ACHD patients, but many aspects, especially risk stratification and treatment considerations, remain unclear. In this article, we aim to discuss the broad impact of COVID-19 on ACHD patients, focusing specifically on pathophysiology, risk stratification for work, self-isolation, hospitalization, impact on pregnancy, psychosocial health, and longer-term implications for the provision of ACHD care.},
}

Adult
*COVID-19
*Cardiovascular Diseases
*Heart Defects, Congenital/complications/epidemiology/therapy
Humans
Pandemics
SARS-CoV-2

@article {pmid33295471,
year = {2020},
author = {Marques-Santos, C and Avila, WS and Carvalho, RCM and Lucena, AJG and Freire, CMV and Alexandre, ERG and Campanharo, FF and Rivera, MAMR and Costa, MENC and Castro, ML},
title = {Position Statement on COVID-19 and Pregnancy in Women with Heart Disease Department of Women Cardiology of the Brazilian Society of Cardiology - 2020.},
journal = {Arquivos brasileiros de cardiologia},
volume = {115},
number = {5},
pages = {975-986},
pmid = {33295471},
issn = {1678-4170},
mesh = {Brazil ; *COVID-19 ; *Cardiology ; Female ; *Heart Diseases ; Humans ; Pandemics ; Practice Guidelines as Topic ; Pregnancy ; *Pregnancy Complications, Neoplastic ; SARS-CoV-2 ; Societies, Medical ; },
}

Brazil
*COVID-19
*Cardiology
Female
*Heart Diseases
Humans
Pandemics
Practice Guidelines as Topic
Pregnancy
*Pregnancy Complications, Neoplastic
SARS-CoV-2
Societies, Medical

@article {pmid33178656,
year = {2020},
author = {Bhaskar, S and Bradley, S and Chattu, VK and Adisesh, A and Nurtazina, A and Kyrykbayeva, S and Sakhamuri, S and Yaya, S and Sunil, T and Thomas, P and Mucci, V and Moguilner, S and Israel-Korn, S and Alacapa, J and Mishra, A and Pandya, S and Schroeder, S and Atreja, A and Banach, M and Ray, D},
title = {Telemedicine Across the Globe-Position Paper From the COVID-19 Pandemic Health System Resilience PROGRAM (REPROGRAM) International Consortium (Part 1).},
journal = {Frontiers in public health},
volume = {8},
number = {},
pages = {556720},
pmid = {33178656},
issn = {2296-2565},
mesh = {*COVID-19 ; Humans ; Pandemics/prevention & control ; Public Health ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {Coronavirus disease 2019 (COVID-19) has accelerated the adoption of telemedicine globally. The current consortium critically examines the telemedicine frameworks, identifies gaps in its implementation and investigates the changes in telemedicine framework/s during COVID-19 across the globe. Streamlining of global public health preparedness framework that is interoperable and allow for collaboration and sharing of resources, in which telemedicine is an integral part of the public health response during outbreaks such as COVID-19, should be pursued. With adequate reinforcement, telemedicine has the potential to act as the "safety-net" of our public health response to an outbreak. Our focus on telemedicine must shift to the developing and under-developing nations, which carry a disproportionate burden of vulnerable communities who are at risk due to COVID-19.},
}

*COVID-19
Humans
Pandemics/prevention & control
Public Health
SARS-CoV-2
*Telemedicine

@article {pmid33123943,
year = {2021},
author = {Defrancesco, M and Bancher, C and Dal-Bianco, P and Hinterhuber, H and Schmidt, R and Struhal, W and Ransmayr, G and Stögmann, E and Marksteiner, J},
title = {[Position paper of the Austrian Alzheimer Association (Österreichische Alzheimer Gesellschaft, ÖAG) : Effects of the COVID-19 pandemic in Austria on people with dementia and their care environment-problem areas, recommendations, and strategies].},
journal = {Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater},
volume = {35},
number = {1},
pages = {35-47},
pmid = {33123943},
issn = {2194-1327},
mesh = {Aged ; Aged, 80 and over ; *Alzheimer Disease/therapy ; Austria ; *COVID-19/epidemiology ; Communicable Disease Control ; *Dementia/therapy ; Humans ; *Pandemics ; Practice Guidelines as Topic ; SARS-CoV-2 ; },
abstract = {Older adults are particularly affected by the current COVID-19 (SARS-CoV-2) pandemic. The risk of dying from COVID-19 increases with age and is often associated with pre-existing health conditions. Globally, more than 50 million-in Austria currently approximately 140,000 people-suffer from dementia. The co-occurrence of dementia as a "pandemic of old age" together with the COVID-19 pandemic has a double impact on persons living with dementia and their caregivers. The COVID-19 pandemic poses major challenges for individuals with dementia and their caregivers: (1) People with dementia have limited access to information on COVID-19, may have difficulties with protective measures such as wearing masks and in remembering safety regulations. (2) People with dementia live alone or with their family, or are institutionalized. To reduce the chance of infection among older people in nursing homes, Austrian local authorities have banned visitors to nursing homes and long-term care facilities and implemented strict social-distancing measures. As a result, older people lost face-to-face contact with their family members, became isolated and social activities stopped. Consequently, anxiety, stress and serious concerns about infections among staff in nursing homes increased and they developed signs of exhaustion and burnout during the full lockdown of the facilities. Thus, due to the emerging COVID-19 crisis, the Austrian Alzheimer Association (Österreichische Alzheimer Gesellschaft, ÖAG) and international societies developed recommendations to support people living with dementia and their caregivers on various issues of physical and mental health.},
}

Aged
Aged, 80 and over
*Alzheimer Disease/therapy
Austria
*COVID-19/epidemiology
Communicable Disease Control
*Dementia/therapy
Humans
*Pandemics
Practice Guidelines as Topic
SARS-CoV-2

@article {pmid33075144,
year = {2021},
author = {Klimek, L and Jutel, M and Bousquet, J and Agache, I and Akdis, CA and Hox, V and Gevaert, P and Tomazic, PV and Rondon, C and Cingi, C and Toppila-Salmi, S and Karavelia, A and Bozkurt, B and Förster-Ruhrmann, U and Becker, S and Chaker, AM and Wollenberg, B and Mösges, R and Huppertz, T and Hagemann, J and Bachert, C and Fokkens, W},
title = {Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.},
journal = {Allergy},
volume = {76},
number = {3},
pages = {677-688},
doi = {10.1111/all.14629},
pmid = {33075144},
issn = {1398-9995},
mesh = {Adrenal Cortex Hormones/administration & dosage ; Asthma/drug therapy ; Biological Products/therapeutic use ; COVID-19/*epidemiology ; Chronic Disease ; Humans ; Nasal Polyps/drug therapy ; Rhinitis/*drug therapy ; *SARS-CoV-2 ; Sinusitis/*drug therapy ; },
abstract = {BACKGROUND: Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID-19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type-2 (T2) inflammation endotypes.

METHODS: The current knowledge on COVID-19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet.

RESULTS: Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID-19 pandemic.

CONCLUSION: Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.},
}

Adrenal Cortex Hormones/administration & dosage
Asthma/drug therapy
Biological Products/therapeutic use
COVID-19/*epidemiology
Chronic Disease
Humans
Nasal Polyps/drug therapy
Rhinitis/*drug therapy
*SARS-CoV-2
Sinusitis/*drug therapy

@article {pmid33027040,
year = {2020},
author = {Bossuyt, X and Damoiseaux, J and Rasmussen, N and van Paassen, P and Hellmich, B and Baslund, B and Blockmans, D and Vermeersch, P and Lopez-Hoyos, M and Vercammen, M and Barret, E and Hammar, F and Leinfelder, U and Mahler, M and Olschowka, N and Roggenbuck, D and Schlumberger, W and Walker, R and Rönnelid, J and Cohen Tervaert, JW and Csernok, E and Fierz, W and , },
title = {Harmonization of antineutrophil cytoplasmic antibodies (ANCA) testing by reporting test result-specific likelihood ratios: position paper.},
journal = {Clinical chemistry and laboratory medicine},
volume = {59},
number = {2},
pages = {e35-e39},
doi = {10.1515/cclm-2020-1178},
pmid = {33027040},
issn = {1437-4331},
mesh = {Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood/*diagnosis/immunology ; Antibodies, Antineutrophil Cytoplasmic/*blood ; Calibration ; Data Interpretation, Statistical ; Diagnosis, Differential ; Humans ; Immunoassay/methods/*standards ; Likelihood Functions ; Myeloblastin/immunology ; Peroxidase/immunology ; Reference Standards ; Sensitivity and Specificity ; },
}

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood/*diagnosis/immunology
Antibodies, Antineutrophil Cytoplasmic/*blood
Calibration
Data Interpretation, Statistical
Diagnosis, Differential
Humans
Immunoassay/methods/*standards
Likelihood Functions
Myeloblastin/immunology
Peroxidase/immunology
Reference Standards
Sensitivity and Specificity

@article {pmid33014958,
year = {2020},
author = {Bhaskar, S and Bradley, S and Chattu, VK and Adisesh, A and Nurtazina, A and Kyrykbayeva, S and Sakhamuri, S and Moguilner, S and Pandya, S and Schroeder, S and Banach, M and Ray, D},
title = {Telemedicine as the New Outpatient Clinic Gone Digital: Position Paper From the Pandemic Health System REsilience PROGRAM (REPROGRAM) International Consortium (Part 2).},
journal = {Frontiers in public health},
volume = {8},
number = {},
pages = {410},
pmid = {33014958},
issn = {2296-2565},
mesh = {*Ambulatory Care Facilities ; COVID-19/*prevention & control ; Health Personnel ; Humans ; Pandemics ; Physical Distancing ; Telemedicine/*trends ; Videoconferencing ; },
abstract = {Technology has acted as a great enabler of patient continuity through remote consultation, ongoing monitoring, and patient education using telephone and videoconferencing in the coronavirus disease 2019 (COVID-19) era. The devastating impact of COVID-19 is bound to prevail beyond its current reign. The vulnerable sections of our community, including the elderly, those from lower socioeconomic backgrounds, those with multiple comorbidities, and immunocompromised patients, endure a relatively higher burden of a pandemic such as COVID-19. The rapid adoption of different technologies across countries, driven by the need to provide continued medical care in the era of social distancing, has catalyzed the penetration of telemedicine. Limiting the exposure of patients, healthcare workers, and systems is critical in controlling the viral spread. Telemedicine offers an opportunity to improve health systems delivery, access, and efficiency. This article critically examines the current telemedicine landscape and challenges in its adoption, toward remote/tele-delivery of care, across various medical specialties. The current consortium provides a roadmap and/or framework, along with recommendations, for telemedicine uptake and implementation in clinical practice during and beyond COVID-19.},
}

*Ambulatory Care Facilities
COVID-19/*prevention & control
Health Personnel
Humans
Pandemics
Physical Distancing
Telemedicine/*trends
Videoconferencing

@article {pmid32945570,
year = {2020},
author = {Bryant, PA and Rogers, BA and Cowan, R and Bowen, AC and Pollard, J and , },
title = {Planning and clinical role of acute medical home care services for COVID-19: consensus position statement by the Hospital-in-the-Home Society Australasia.},
journal = {Internal medicine journal},
volume = {50},
number = {10},
pages = {1267-1271},
pmid = {32945570},
issn = {1445-5994},
mesh = {Australasia/epidemiology ; Betacoronavirus ; COVID-19 ; Communication ; Coronavirus Infections/*epidemiology/*therapy ; Equipment and Supplies, Hospital/supply & distribution ; Health Workforce/organization & administration ; Home Care Services/*organization & administration ; Humans ; Infection Control/organization & administration ; Occupational Exposure/prevention & control ; Pandemics ; Patient-Centered Care/organization & administration ; Pneumonia, Viral/*epidemiology/*therapy ; SARS-CoV-2 ; Workload ; },
abstract = {During a pandemic when hospitals are stretched and patients need isolation, the role of hospital-in-the-home (HITH) providing acute medical care at home has never been more relevant. We aimed to define and address the challenges to acute home care services posed by the COVID-19 pandemic. Planning for service operation involves staffing, equipment availability and cleaning, upskilling in telehealth and communication. Planning for clinical care involves maximising cohorts of patients without COVID-19 and new clinical pathways for patients with COVID-19. The risk of SARS-CoV-2 transmission, specific COVID-19 clinical pathways and the well-being of patients and staff should be addressed in advance.},
}

Australasia/epidemiology
Betacoronavirus
COVID-19
Communication
Coronavirus Infections/*epidemiology/*therapy
Equipment and Supplies, Hospital/supply & distribution
Health Workforce/organization & administration
Home Care Services/*organization & administration
Humans
Infection Control/organization & administration
Occupational Exposure/prevention & control
Pandemics
Patient-Centered Care/organization & administration
Pneumonia, Viral/*epidemiology/*therapy
SARS-CoV-2
Workload

@article {pmid32941344,
year = {2020},
author = {Oliva, A and Caputo, M and Grassi, S and Vetrugno, G and Marazza, M and Ponzanelli, G and Cauda, R and Scambia, G and Forti, G and Bellantone, R and Pascali, VL},
title = {Liability of Health Care Professionals and Institutions During COVID-19 Pandemic in Italy: Symposium Proceedings and Position Statement.},
journal = {Journal of patient safety},
volume = {16},
number = {4},
pages = {e299-e302},
pmid = {32941344},
issn = {1549-8425},
mesh = {Betacoronavirus/isolation & purification ; COVID-19 ; Coronavirus Infections/epidemiology ; Health Personnel/*legislation & jurisprudence ; Humans ; Italy/epidemiology ; *Legislation, Hospital ; *Liability, Legal ; Pandemics/*legislation & jurisprudence ; Pneumonia, Viral/epidemiology ; SARS-CoV-2 ; },
abstract = {BACKGROUND: On May 12, 2020, a symposium titled "Liability of healthcare professionals and institutions during COVID-19 pandemic" was held in Italy with the participation of national experts in malpractice law, hospital management, legal medicine, and clinical risk management. The symposium's rationale was the highly likely inflation of criminal and civil proceedings concerning alleged errors committed by health care professionals and decision makers during the COVID-19 pandemic. Its aim was to identify and discuss the main issues of legal and medicolegal interest and thus to find solid solutions in the spirit of preparedness planning.

METHODS: There were 5 main points of discussion: (A) how to judge errors committed during the pandemic because of the application of protocols and therapies based on no or weak evidence of efficacy, (B) whether hospital managers can be considered liable for infected health care professionals who were not given adequate personal protective equipment, (C) whether health care professionals and institutions can be considered liable for cases of infected inpatients who claim that the infection was transmitted in a hospital setting, (D) whether health care institutions and hospital managers can be considered liable for the hotspots in long-term care facilities/care homes, and (E) whether health care institutions and hospital managers can be considered liable for the worsening of chronic diseases.

RESULTS AND CONCLUSION: Limitation of the liability to the cases of gross negligence (with an explicit definition of this term), a no-fault system with statal indemnities for infected cases, and a rigorous methodology for the expert witnesses were proposed as key interventions for successfully facing future proceedings.},
}

Betacoronavirus/isolation & purification
COVID-19
Coronavirus Infections/epidemiology
Health Personnel/*legislation & jurisprudence
Humans
Italy/epidemiology
*Legislation, Hospital
*Liability, Legal
Pandemics/*legislation & jurisprudence
Pneumonia, Viral/epidemiology
SARS-CoV-2

@article {pmid32933562,
year = {2020},
author = {Villani, A and Bozzola, E and Staiano, A and Agostiniani, R and Del Vecchio, A and Zamperini, N and Marino, F and Vecchio, D and Corsello, G},
title = {Facial masks in children: the position statement of the Italian pediatric society.},
journal = {Italian journal of pediatrics},
volume = {46},
number = {1},
pages = {132},
pmid = {32933562},
issn = {1824-7288},
mesh = {*Betacoronavirus ; COVID-19 ; Child ; *Consensus ; Coronavirus Infections/epidemiology/*transmission ; Disease Transmission, Infectious/*prevention & control ; Equipment Design ; Humans ; Infection Control/*organization & administration ; Masks/standards/*supply & distribution ; Pandemics ; Pneumonia, Viral/epidemiology/*transmission ; SARS-CoV-2 ; },
abstract = {Facial masks may be one of the most cost-effective strategies to prevent the diffusion of COVID 19 infection. Nevertheless, fake news are spreading, alerting parents on dangerous side effects in children, such as hypercapnia, hypoxia, gut dysbiosis and immune system weakness. Aim of the Italian Pediatric Society statement is to face misconception towards the use of face masks and to spread scientific trustable information.},
}

*Betacoronavirus
COVID-19
Child
*Consensus
Coronavirus Infections/epidemiology/*transmission
Disease Transmission, Infectious/*prevention & control
Equipment Design
Humans
Infection Control/*organization & administration
Masks/standards/*supply & distribution
Pandemics
Pneumonia, Viral/epidemiology/*transmission
SARS-CoV-2

@article {pmid32890777,
year = {2020},
author = {Greenspan, H and San José Estépar, R and Niessen, WJ and Siegel, E and Nielsen, M},
title = {Position paper on COVID-19 imaging and AI: From the clinical needs and technological challenges to initial AI solutions at the lab and national level towards a new era for AI in healthcare.},
journal = {Medical image analysis},
volume = {66},
number = {},
pages = {101800},
pmid = {32890777},
issn = {1361-8423},
support = {R01 HL149877/HL/NHLBI NIH HHS/United States ; R21 HL140422/HL/NHLBI NIH HHS/United States ; },
mesh = {Algorithms ; Artificial Intelligence/*trends ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/*diagnostic imaging ; Diagnostic Imaging/*methods ; Humans ; Pandemics ; Pneumonia, Viral/*diagnostic imaging ; SARS-CoV-2 ; },
abstract = {In this position paper, we provide a collection of views on the role of AI in the COVID-19 pandemic, from clinical requirements to the design of AI-based systems, to the translation of the developed tools to the clinic. We highlight key factors in designing system solutions - per specific task; as well as design issues in managing the disease at the national level. We focus on three specific use-cases for which AI systems can be built: early disease detection, management in a hospital setting, and building patient-specific predictive models that require the combination of imaging with additional clinical data. Infrastructure considerations and population modeling in two European countries will be described. This pandemic has made the practical and scientific challenges of making AI solutions very explicit. A discussion concludes this paper, with a list of challenges facing the community in the AI road ahead.},
}

Algorithms
Artificial Intelligence/*trends
Betacoronavirus
COVID-19
Coronavirus Infections/*diagnostic imaging
Diagnostic Imaging/*methods
Humans
Pandemics
Pneumonia, Viral/*diagnostic imaging
SARS-CoV-2

@article {pmid32882035,
year = {2020},
author = {Rutkowski, JL and Camm, DP and El Chaar, E},
title = {AAID White Paper: Management of the Dental Implant Patient During the COVID-19 Pandemic and Beyond.},
journal = {The Journal of oral implantology},
volume = {46},
number = {5},
pages = {454-466},
doi = {10.1563/aaid-joi-D-20-00316},
pmid = {32882035},
issn = {0160-6972},
mesh = {*Betacoronavirus ; *COVID-19 ; *Dental Implants ; Humans ; Pandemics ; United States ; },
abstract = {The scientific community's understanding of how the SARS-CoV-2 virus is transmitted and how to best mitigate its spread is improving daily. To help protect patients from acquiring COVID-19 from a dental office nosocomial infection, many state or local governments have classified dental treatments as "nonessential" and have paused routine dental care. Dentists have been instructed to perform only procedures designated as emergencies. Unfortunately, there is not a good understanding of what a dental emergency is among governmental leaders. What a government agency may perceive as an elective procedure may be seen as "essential" by the dental clinician responsible for maintaining the oral health of the patient. Each dental specialty understands the effects delayed care has on a patient's oral and systemic health. Dentistry has made extensive progress in improving oral health through prevention of the dental emergency. The dental profession must work together to prevent the reversal of the progress dentistry and patients have made. This American Academy of Implant Dentistry (AAID) White Paper discusses what COVID-19 is and how it impacts dental treatments, presents guidelines for dentistry in general and for dental implant related treatments, specifically. Recommendations for implant dentistry include the following: (1) what constitutes a dental implant related emergency, (2) how patients should be screened and triaged, (3) what personal protective equipment is necessary, (4) how operatories should be equipped, (5) what equipment should be used, and (6) what, when, and how procedures can be performed. This paper is intended to provide guidance for the dental implant practice so patients and dental health care providers can be safe, and offices can remain open and viable during the pandemic.},
}

*Betacoronavirus
*COVID-19
*Dental Implants
Humans
Pandemics
United States

@article {pmid32876200,
year = {2020},
author = {Soeiro, AM and Leal, TCAT and Pereira, MP and Lima, EG and Figueiredo, ACBDS and Petriz, JLF and Precoma, DB and Serrano, CV},
title = {Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19) - 2020.},
journal = {Arquivos brasileiros de cardiologia},
volume = {115},
number = {2},
pages = {292-301},
pmid = {32876200},
issn = {1678-4170},
mesh = {Anticoagulants/*therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/*drug therapy ; Humans ; Pandemics ; Platelet Aggregation Inhibitors/*therapeutic use ; Pneumonia, Viral/*drug therapy ; SARS-CoV-2 ; },
}

Anticoagulants/*therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections/*drug therapy
Humans
Pandemics
Platelet Aggregation Inhibitors/*therapeutic use
Pneumonia, Viral/*drug therapy
SARS-CoV-2

@article {pmid32871013,
year = {2020},
author = {Noel, JM and Jackson, CW},
title = {ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder.},
journal = {American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists},
volume = {77},
number = {24},
pages = {2114-2132},
doi = {10.1093/ajhp/zxaa303},
pmid = {32871013},
issn = {1535-2900},
mesh = {Adult ; Antipsychotic Agents/*administration & dosage/adverse effects ; Humans ; Psychotic Disorders/*drug therapy ; Schizophrenia/*drug therapy ; Societies, Pharmaceutical ; United States ; },
abstract = {In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.},
}

Adult
Antipsychotic Agents/*administration & dosage/adverse effects
Humans
Psychotic Disorders/*drug therapy
Schizophrenia/*drug therapy
Societies, Pharmaceutical
United States

@article {pmid32825892,
year = {2020},
author = {Vora, A and Arora, VK and Behera, D and Tripathy, SK},
title = {White paper on Ivermectin as a potential therapy for COVID-19.},
journal = {The Indian journal of tuberculosis},
volume = {67},
number = {3},
pages = {448-451},
pmid = {32825892},
issn = {0019-5707},
mesh = {Antiparasitic Agents/therapeutic use ; *Betacoronavirus ; COVID-19 ; Coronavirus Infections/*drug therapy ; Humans ; Ivermectin/*therapeutic use ; Pandemics ; Pneumonia, Viral/*drug therapy ; Risk Factors ; SARS-CoV-2 ; Treatment Outcome ; },
abstract = {A group of senior doctors with vast clinical experience met on 19th July'20 under the aegis of Academy of Advanced Medical Education. The panel looked at Ivermectin, one of the old molecule and evaluated it's use in COVID 19 (Novel Coronavirus Disease 2019) management. After critical panel discussion, all the attending doctors came to a conclusion that Ivermectin can be a potential molecule for prophylaxis and treatment of people infected with Coronavirus, owing to its anti-viral properties coupled with effective cost, availability and good tolerability and safety.},
}

Antiparasitic Agents/therapeutic use
*Betacoronavirus
COVID-19
Coronavirus Infections/*drug therapy
Humans
Ivermectin/*therapeutic use
Pandemics
Pneumonia, Viral/*drug therapy
Risk Factors
SARS-CoV-2
Treatment Outcome

@article {pmid32823368,
year = {2020},
author = {Pfaar, O and Klimek, L and Worm, M and Bergmann, KC and Bieber, T and Buhl, R and Buters, J and Darsow, U and Keil, T and Kleine-Tebbe, J and Lau, S and Maurer, M and Merk, H and Mösges, R and Saloga, J and Staubach, P and Stute, P and Rabe, K and Rabe, U and Vogelmeier, C and Biedermann, T and Jung, K and Schlenter, W and Ring, J and Chaker, A and Wehrmann, W and Becker, S and Mülleneisen, N and Nemat, K and Czech, W and Wrede, H and Brehler, R and Fuchs, T and Tomazic, PV and Aberer, W and Fink-Wagner, A and Horak, F and Wöhrl, S and Niederberger-Leppin, V and Pali-Schöll, I and Pohl, W and Roller-Wirnsberger, R and Spranger, O and Valenta, R and Akdis, M and Akdis, C and Hoffmann-Sommergruber, K and Jutel, M and Matricardi, P and Spertini, F and Khaltaev, N and Michel, JP and Nicod, L and Schmid-Grendelmeier, P and Hamelmann, E and Jakob, T and Werfel, T and Wagenmann, M and Taube, C and Gerstlauer, M and Vogelberg, C and Bousquet, J and Zuberbier, T},
title = {[Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)].},
journal = {Laryngo- rhino- otologie},
volume = {99},
number = {10},
pages = {676-679},
doi = {10.1055/a-1170-8426},
pmid = {32823368},
issn = {1438-8685},
mesh = {*Betacoronavirus ; COVID-19 ; *Coronavirus Infections ; Desensitization, Immunologic ; Humans ; *Pandemics ; *Pneumonia, Viral ; SARS-CoV-2 ; },
}

*Betacoronavirus
COVID-19
*Coronavirus Infections
Desensitization, Immunologic
Humans
*Pandemics
*Pneumonia, Viral
SARS-CoV-2

@article {pmid32754159,
year = {2020},
author = {Bhaskar, S and Sinha, A and Banach, M and Mittoo, S and Weissert, R and Kass, JS and Rajagopal, S and Pai, AR and Kutty, S},
title = {Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.},
journal = {Frontiers in immunology},
volume = {11},
number = {},
pages = {1648},
pmid = {32754159},
issn = {1664-3224},
support = {001/WHO_/World Health Organization/International ; },
mesh = {Adrenal Cortex Hormones/therapeutic use ; Angiotensin-Converting Enzyme 2 ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Betacoronavirus/*immunology ; CD4-CD8 Ratio ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; COVID-19 ; Clinical Decision-Making/methods ; Coronavirus Infections/blood/*drug therapy/*immunology/mortality ; Critical Care/*methods ; Critical Illness ; Cytokines/*blood ; Endothelial Cells/metabolism ; Female ; Humans ; Immunocompromised Host ; Interleukin-6/antagonists & inhibitors ; Janus Kinase Inhibitors/therapeutic use ; Male ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/blood/*drug therapy/*immunology/mortality ; SARS-CoV-2 ; Sex Factors ; Thrombosis ; },
abstract = {Cytokine storm is an acute hyperinflammatory response that may be responsible for critical illness in many conditions including viral infections, cancer, sepsis, and multi-organ failure. The phenomenon has been implicated in critically ill patients infected with SARS-CoV-2, the novel coronavirus implicated in COVID-19. Critically ill COVID-19 patients experiencing cytokine storm are believed to have a worse prognosis and increased fatality rate. In SARS-CoV-2 infected patients, cytokine storm appears important to the pathogenesis of several severe manifestations of COVID-19: acute respiratory distress syndrome, thromboembolic diseases such as acute ischemic strokes caused by large vessel occlusion and myocardial infarction, encephalitis, acute kidney injury, and vasculitis (Kawasaki-like syndrome in children and renal vasculitis in adult). Understanding the pathogenesis of cytokine storm will help unravel not only risk factors for the condition but also therapeutic strategies to modulate the immune response and deliver improved outcomes in COVID-19 patients at high risk for severe disease. In this article, we present an overview of the cytokine storm and its implications in COVID-19 settings and identify potential pathways or biomarkers that could be targeted for therapy. Leveraging expert opinion, emerging evidence, and a case-based approach, this position paper provides critical insights on cytokine storm from both a prognostic and therapeutic standpoint.},
}

Adrenal Cortex Hormones/therapeutic use
Angiotensin-Converting Enzyme 2
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Betacoronavirus/*immunology
CD4-CD8 Ratio
CD4-Positive T-Lymphocytes/immunology
CD8-Positive T-Lymphocytes/immunology
COVID-19
Clinical Decision-Making/methods
Coronavirus Infections/blood/*drug therapy/*immunology/mortality
Critical Care/*methods
Critical Illness
Cytokines/*blood
Endothelial Cells/metabolism
Female
Humans
Immunocompromised Host
Interleukin-6/antagonists & inhibitors
Janus Kinase Inhibitors/therapeutic use
Male
Pandemics
Peptidyl-Dipeptidase A/metabolism
Pneumonia, Viral/blood/*drug therapy/*immunology/mortality
SARS-CoV-2
Sex Factors
Thrombosis

@article {pmid32748068,
year = {2020},
author = {Stolbach, A and Mazer-Amirshahi, M and Schwarz, ES and Juurlink, D and Wiegand, TJ and Nelson, LS},
title = {ACMT Position Statement: Caring for Patients with Opioid Use Disorder during Coronavirus Disease Pandemic.},
journal = {Journal of medical toxicology : official journal of the American College of Medical Toxicology},
volume = {16},
number = {4},
pages = {484-486},
pmid = {32748068},
issn = {1937-6995},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/*epidemiology ; Health Services Accessibility ; Humans ; Opioid-Related Disorders/*therapy ; Pandemics ; Pneumonia, Viral/*epidemiology ; SARS-CoV-2 ; Toxicology ; },
}

*Betacoronavirus
COVID-19
Coronavirus Infections/*epidemiology
Health Services Accessibility
Humans
Opioid-Related Disorders/*therapy
Pandemics
Pneumonia, Viral/*epidemiology
SARS-CoV-2
Toxicology

@article {pmid32740024,
year = {2020},
author = {Maculotti, D and Spena, PR and Villa, G},
title = {POSITION STATEMENT ON CARE OF OSTOMY PATIENTS DURING COVID-19 PANDEMIC.},
journal = {Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates},
volume = {43},
number = {4},
pages = {324-326},
doi = {10.1097/SGA.0000000000000539},
pmid = {32740024},
issn = {1538-9766},
mesh = {Ambulatory Care ; *Betacoronavirus ; COVID-19 ; Coronavirus Infections/*epidemiology/prevention & control/transmission ; Hospitalization ; Humans ; Infection Control/*organization & administration ; *Ostomy ; Pandemics/prevention & control ; Patient Selection ; Pneumonia, Viral/*epidemiology/prevention & control/transmission ; SARS-CoV-2 ; },
}

Ambulatory Care
*Betacoronavirus
COVID-19
Coronavirus Infections/*epidemiology/prevention & control/transmission
Hospitalization
Humans
Infection Control/*organization & administration
*Ostomy
Pandemics/prevention & control
Patient Selection
Pneumonia, Viral/*epidemiology/prevention & control/transmission
SARS-CoV-2

@article {pmid32732509,
year = {2020},
author = {Moore, TA},
title = {Overview of the Care of Mothers and Newborns With COVID-19; Joint Position Statement.},
journal = {Advances in neonatal care : official journal of the National Association of Neonatal Nurses},
volume = {20},
number = {4},
pages = {268},
pmid = {32732509},
issn = {1536-0911},
mesh = {American Nurses' Association ; Betacoronavirus ; COVID-19 ; *Coronavirus Infections/epidemiology/prevention & control ; *Evidence-Based Nursing/methods/trends ; Female ; Humans ; Infant, Newborn ; Infection Control/organization & administration ; *Neonatal Nursing/organization & administration/standards ; Organizational Innovation ; *Pandemics/prevention & control ; *Pneumonia, Viral/epidemiology/prevention & control ; *Postnatal Care/methods/organization & administration/trends ; SARS-CoV-2 ; United States ; },
}

American Nurses' Association
Betacoronavirus
COVID-19
*Coronavirus Infections/epidemiology/prevention & control
*Evidence-Based Nursing/methods/trends
Female
Humans
Infant, Newborn
Infection Control/organization & administration
*Neonatal Nursing/organization & administration/standards
Organizational Innovation
*Pandemics/prevention & control
*Pneumonia, Viral/epidemiology/prevention & control
*Postnatal Care/methods/organization & administration/trends
SARS-CoV-2
United States

@article {pmid32719884,
year = {2020},
author = {Gutenbrunner, C and Stokes, EK and Dreinhöfer, K and Monsbakken, J and Clarke, S and Côté, P and Urseau, I and Constantine, D and Tardif, C and Balakrishna, V and Nugraha, B},
title = {Why Rehabilitation must have priority during and after the COVID-19-pandemic: A position statement of the Global Rehabilitation Alliance.},
journal = {Journal of rehabilitation medicine},
volume = {52},
number = {7},
pages = {jrm00081},
doi = {10.2340/16501977-2713},
pmid = {32719884},
issn = {1651-2081},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/prevention & control/*rehabilitation ; Global Health ; Health Services Accessibility/standards ; Humans ; Infection Control/standards ; Pandemics/prevention & control ; Pneumonia, Viral/prevention & control/*rehabilitation ; SARS-CoV-2 ; },
abstract = {COVID-19 has become a pandemic with strong influence on health systems. In many cases it leads to a disruption of rehabilitation service provision. On the other hand, rehabilitation must be an integral part of COVID-19 management. Rehabilitation for COVID-19 should start from acute and early post-acute care and needs to be continued in the post-acute and long-term rehabilitation phase. Of course, it should follow specific safety protocol. Additionally, rehabilitation must be kept available for all other people who are in need. From the perspective of health system, the Global Rehabilitation Alliance urges decision makers to ensure that rehabilitation services will be available for all patients with COVID-19 in the acute, post-acute and long-term phase. Additionally, it must be ensured that all other persons with rehabilitation need have access to rehabilitation services. Rehabilitation services must be equipped with personal protection equipment and follow strict hygiene measures. In particular, rehabilitation must be accessible for vulnerable populations. For that reason, rehabilitation must be kept a health priority during the COVID-19 pandemic and given adequate financial resources. Last but not least, scientific studies should be performed to clarify the impact of the pandemic on rehabilitation services as well as on the needs for rehabilitation of COVID-19 patients.},
}

*Betacoronavirus
COVID-19
Coronavirus Infections/prevention & control/*rehabilitation
Global Health
Health Services Accessibility/standards
Humans
Infection Control/standards
Pandemics/prevention & control
Pneumonia, Viral/prevention & control/*rehabilitation
SARS-CoV-2

@article {pmid32694078,
year = {2020},
author = {Vivas, D and Roldán, V and Esteve-Pastor, MA and Roldán, I and Tello-Montoliu, A and Ruiz-Nodar, JM and Cosín-Sales, J and Gámez, JM and Consuegra, L and Ferreiro, JL and Marín, F and , },
title = {Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology.},
journal = {Revista espanola de cardiologia (English ed.)},
volume = {73},
number = {9},
pages = {749-757},
pmid = {32694078},
issn = {1885-5857},
mesh = {*Betacoronavirus ; COVID-19 ; Cardiology ; Coronavirus Infections/*drug therapy ; Fibrinolytic Agents/*therapeutic use ; Humans ; Pandemics ; Patient Selection ; Pneumonia, Viral/*drug therapy ; SARS-CoV-2 ; Societies, Medical ; Spain ; COVID-19 Drug Treatment ; },
abstract = {The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.},
}

*Betacoronavirus
COVID-19
Cardiology
Coronavirus Infections/*drug therapy
Fibrinolytic Agents/*therapeutic use
Humans
Pandemics
Patient Selection
Pneumonia, Viral/*drug therapy
SARS-CoV-2
Societies, Medical
Spain
COVID-19 Drug Treatment

@article {pmid32675009,
year = {2020},
author = {Torlone, E and Festa, C and Formoso, G and Scavini, M and Sculli, MA and Succurro, E and Sciacca, L and Di Bartolo, P and Purrello, F and Lapolla, A},
title = {Italian recommendations for the diagnosis of gestational diabetes during COVID-19 pandemic: Position statement of the Italian Association of Clinical Diabetologists (AMD) and the Italian Diabetes Society (SID), diabetes, and pregnancy study group.},
journal = {Nutrition, metabolism, and cardiovascular diseases : NMCD},
volume = {30},
number = {9},
pages = {1418-1422},
pmid = {32675009},
issn = {1590-3729},
mesh = {*Betacoronavirus ; Blood Glucose/analysis ; COVID-19 ; Coronavirus Infections/*epidemiology ; Diabetes, Gestational/*diagnosis ; Female ; Glucose Tolerance Test ; Humans ; Italy ; Pandemics ; Pneumonia, Viral/*epidemiology ; Pregnancy ; SARS-CoV-2 ; },
abstract = {AIM: In response to the COVID-19 pandemic, there is a need for substantial changes in the procedures for accessing healthcare services. Even in the current pandemic, we should not reduce our attention towards the diagnosis and treatment of GDM. The purpose of this document is to provide a temporary guide for GDM screening, replacing the current guidelines when it is not possible to implement standard GDM screening because of an unfavorable risk/benefit ratio for pregnant women or when usual laboratory facilities are not available.

DATA SYNTHESIS: At the first visit during pregnancy, we must exclude the presence of "Overt diabetes" in all women. The criteria for the diagnosis of overt diabetes are either fasting plasma glucose ≥126 mg/dL, or random plasma glucose ≥200 mg/dL, or glycated hemoglobin ≥6.5%. When the screening procedure (OGTT) cannot be safely performed, the diagnosis of GDM is acceptable if fasting plasma glucose is ≥ 92 mg/dL. In order to consider the impaired fasting glucose as an acceptable surrogate for the diagnosis of GDM, the fasting glucose measurement should be performed within the recommended time windows for the risk level (high or medium risk).

CONCLUSIONS: The changes to the screening procedure for GDM reported below are specifically produced in response to the health emergency of the COVID-19 pandemic. Therefore, these recommended changes should cease to be in effect and should be replaced by current national guidelines when the healthcare authorities declare the end of this emergency.},
}

*Betacoronavirus
Blood Glucose/analysis
COVID-19
Coronavirus Infections/*epidemiology
Diabetes, Gestational/*diagnosis
Female
Glucose Tolerance Test
Humans
Italy
Pandemics
Pneumonia, Viral/*epidemiology
Pregnancy
SARS-CoV-2

@article {pmid32674177,
year = {2020},
author = {Kolditz, M and Dellweg, D and Geerdes-Fenge, H and Lepper, PM and Schaberg, T and Ewig, S and Pfeifer, M and Bauer, T},
title = {[Treatment with Dexamethasone in Patients with COVID-19 - A Position Paper of the German Respiratory Society (DGP)].},
journal = {Pneumologie (Stuttgart, Germany)},
volume = {74},
number = {8},
pages = {493-495},
pmid = {32674177},
issn = {1438-8790},
mesh = {Anti-Inflammatory Agents/*therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus/*isolation & purification ; Coronavirus Infections/diagnosis/*drug therapy ; Dexamethasone/*therapeutic use ; Germany ; Humans ; *Pandemics ; Pneumonia, Viral/diagnosis/*drug therapy ; *Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; Treatment Outcome ; COVID-19 Drug Treatment ; },
}

Anti-Inflammatory Agents/*therapeutic use
Betacoronavirus
COVID-19
Coronavirus/*isolation & purification
Coronavirus Infections/diagnosis/*drug therapy
Dexamethasone/*therapeutic use
Germany
Humans
*Pandemics
Pneumonia, Viral/diagnosis/*drug therapy
*Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical
Treatment Outcome
COVID-19 Drug Treatment

@article {pmid32643767,
year = {2020},
author = {Gralnek, IM and Hassan, C and Beilenhoff, U and Antonelli, G and Ebigbo, A and Pellisé, M and Arvanitakis, M and Bhandari, P and Bisschops, R and Van Hooft, JE and Kaminski, MF and Triantafyllou, K and Webster, G and Voiosu, AM and Pohl, H and Dunkley, I and Fehrke, B and Gazic, M and Gjergek, T and Maasen, S and Waagenes, W and de Pater, M and Ponchon, T and Siersema, PD and Messmann, H and Dinis-Ribeiro, M},
title = {ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: An update on guidance during the post-lockdown phase and selected results from a membership survey.},
journal = {Endoscopy},
volume = {52},
number = {10},
pages = {891-898},
pmid = {32643767},
issn = {1438-8812},
mesh = {Humans ; Betacoronavirus ; *Coronavirus Infections ; COVID-19 ; *Endoscopy, Gastrointestinal ; *Pandemics ; *Pneumonia, Viral ; SARS-CoV-2 ; Surveys and Questionnaires ; },
}

Humans
Betacoronavirus
*Coronavirus Infections
COVID-19
*Endoscopy, Gastrointestinal
*Pandemics
*Pneumonia, Viral
SARS-CoV-2
Surveys and Questionnaires

@article {pmid32638902,
year = {2020},
author = {Guimarães, HP and Timerman, S and Rodrigues, RDR and Corrêa, TD and Schubert, DUC and Freitas, AP and Rea Neto, Á and Polastri, TF and Vane, MF and Couto, TB and Brandão, ACA and Giannetti, NS and Timerman, T and Hajjar, LA and Bacal, F and Lopes, MACQ},
title = {Position Statement: Cardiopulmonary Resuscitation of Patients with Confirmed or Suspected COVID-19 - 2020.},
journal = {Arquivos brasileiros de cardiologia},
volume = {114},
number = {6},
pages = {1078-1087},
pmid = {32638902},
issn = {1678-4170},
mesh = {Advisory Committees ; Betacoronavirus ; Brazil/epidemiology ; COVID-19 ; Cardiopulmonary Resuscitation/methods/*standards ; *Coronavirus ; Coronavirus Infections/diagnosis/epidemiology/*therapy ; Humans ; *Pandemics ; Pneumonia, Viral/diagnosis/epidemiology/*therapy ; *Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; United States ; },
abstract = {Care for patients with cardiac arrest in the context of the coronavirus disease 2019 (COVID-19) pandemic has several unique aspects that warrant particular attention. This joint position statement by the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Society of Cardiology (SBC), Brazilian Association of Intensive Care Medicine (AMIB), and Brazilian Society of Anesthesiology (SBA), all official societies representing the corresponding medical specialties affiliated with the Brazilian Medical Association (AMB), provides recommendations to guide health care workers in the current context of limited robust evidence, aiming to maximize the protection of staff and patients alike. It is essential that full aerosol precautions, which include wearing appropriate personal protective equipment, be followed during resuscitation. It is also imperative that potential causes of cardiac arrest of particular interest in this patient population, especially hypoxia, cardiac arrhythmias associated with QT prolongation, and myocarditis, be considered and addressed. An advanced invasive airway device should be placed early. Use of HEPA filters at the bag-valve interface is mandatory. Management of cardiac arrest occurring during mechanical ventilation or during prone positioning demands particular ventilator settings and rescuer positioning for chest compressions which deviate from standard cardiopulmonary resuscitation techniques. Apart from these logistical issues, care should otherwise follow national and international protocols and guidelines, namely the 2015 International Liaison Committee on Resuscitation (ILCOR) and 2019 American Heart Association (AHA) guidelines and the 2019 Update to the Brazilian Society of Cardiology Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Guideline.},
}

Advisory Committees
Betacoronavirus
Brazil/epidemiology
COVID-19
Cardiopulmonary Resuscitation/methods/*standards
*Coronavirus
Coronavirus Infections/diagnosis/epidemiology/*therapy
Humans
*Pandemics
Pneumonia, Viral/diagnosis/epidemiology/*therapy
*Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical
United States

@article {pmid32623686,
year = {2020},
author = {Stier, C and Lopez-Nava, G and Neto, MG and Thompson, CC and Campos, J and Khoursheed, M and Lakdawala, M and Ramos, A and Abu Dayyeh, BK},
title = {IFSO Endoscopy Committee Position Statement on the Practice of Bariatric Endoscopy During the COVID-19 Pandemic.},
journal = {Obesity surgery},
volume = {30},
number = {11},
pages = {4179-4186},
pmid = {32623686},
issn = {1708-0428},
mesh = {*Bariatrics ; *Betacoronavirus ; COVID-19 ; Coronavirus Infections/epidemiology/*prevention & control/transmission ; *Endoscopy ; Humans ; Infection Control/*organization & administration ; Obesity, Morbid/*surgery ; Pandemics/*prevention & control ; Patient Selection ; Pneumonia, Viral/epidemiology/*prevention & control/transmission ; Practice Guidelines as Topic ; SARS-CoV-2 ; },
abstract = {COVID-19 (Coronavirus disease 2019) caused by SARS-CoV-2 has become a global pandemic. Obesity is a risk factor for severe disease, and the practice of endoscopy poses special challenges and risks of SARS-CoV-2 transmission to patients and providers given the evolving role of the gastrointestinal tract in viral transmission and aerosol generation during endoscopic procedures. It is therefore necessary to distinguish between urgent interventions that cannot be postponed despite the risks during the pandemic and, in contrast, purely elective interventions that could be deferred in order to minimize transmission risks during a time of infection surge and limited access. Semi-urgent bariatric procedures have an intermediate position. Since the chronological course of the pandemic is still unpredictable, these interventions were defined according to whether or not they should be performed within a nominal 8-week period. In this position statement, the IFSO Endoscopy Committee offers guidance on navigating bariatric endoscopic procedures in patients with obesity during the COVID-19 pandemic, in the hope of mitigating the risk of SARS-CoV-2 transmission to vulnerable patients and healthcare workers. These recommendations may evolve as the pandemic progresses.},
}

*Bariatrics
*Betacoronavirus
COVID-19
Coronavirus Infections/epidemiology/*prevention & control/transmission
*Endoscopy
Humans
Infection Control/*organization & administration
Obesity, Morbid/*surgery
Pandemics/*prevention & control
Patient Selection
Pneumonia, Viral/epidemiology/*prevention & control/transmission
Practice Guidelines as Topic
SARS-CoV-2

@article {pmid32620315,
year = {2020},
author = {Miranda-Zazueta, G and González-Regueiro, JA and García-Juárez, I and Moctezuma-Velázquez, C and López-Díaz, FJ and Pérez-González, B and Uscanga-Domínguez, LF and Peláez-Luna, M},
title = {Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Position statement within the framework of the SARS-CoV-2 (COVID-19) pandemic.},
journal = {Revista de gastroenterologia de Mexico (English)},
volume = {85},
number = {3},
pages = {312-320},
pmid = {32620315},
issn = {2255-534X},
mesh = {COVID-19 ; Coronavirus Infections/*complications ; Humans ; Immunosuppressive Agents/*adverse effects/*therapeutic use ; Liver Diseases/complications/*drug therapy ; Liver Transplantation ; Pancreas Transplantation ; Pancreatic Diseases/complications/*drug therapy ; *Pandemics ; Pneumonia, Viral/*complications ; },
abstract = {The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) virus. COVID-19 affected more than 6million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome. Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection. Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy.},
}

COVID-19
Coronavirus Infections/*complications
Humans
Immunosuppressive Agents/*adverse effects/*therapeutic use
Liver Diseases/complications/*drug therapy
Liver Transplantation
Pancreas Transplantation
Pancreatic Diseases/complications/*drug therapy
*Pandemics
Pneumonia, Viral/*complications

@article {pmid32617893,
year = {2020},
author = {Farmer, BM and Cole, JB and Olives, TD and Farrell, NM and Rao, R and Nelson, LS and Mazer-Amirshahi, M and Stolbach, AI},
title = {ACMT Position Statement: Medication Administration and Safety During the Response to COVID-19 Pandemic.},
journal = {Journal of medical toxicology : official journal of the American College of Medical Toxicology},
volume = {16},
number = {4},
pages = {481-483},
pmid = {32617893},
issn = {1937-6995},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/drug therapy/*epidemiology/prevention & control ; Health Personnel/education ; Humans ; Pandemics/prevention & control ; Personal Protective Equipment ; Pneumonia, Viral/drug therapy/*epidemiology/prevention & control ; SARS-CoV-2 ; Toxicology ; },
}

*Betacoronavirus
COVID-19
Coronavirus Infections/drug therapy/*epidemiology/prevention & control
Health Personnel/education
Humans
Pandemics/prevention & control
Personal Protective Equipment
Pneumonia, Viral/drug therapy/*epidemiology/prevention & control
SARS-CoV-2
Toxicology

@article {pmid32613918,
year = {2020},
author = {Geneid, A and Nawka, T and Schindler, A and Oguz, H and Chrobok, V and Calcinoni, O and Am Zehnhoff-Dinnesen, A and Neumann, K and Farahat, M and Abou-Elsaad, T and Moerman, M and Chavez, E and Fishman, J and Yazaki, R and Arnold, B and Frajkova, Z and Graf, S and Pflug, C and Drsata, J and Desuter, G and Samuelsson, C and Tedla, M and Costello, D and Sjögren, E and Hess, M and Kinnari, T and Rubin, J},
title = {Union of the European Phoniatricians' position statement on the exit strategy of phoniatric and laryngological services: staying safe and getting back to normal after the peak of coronavirus disease 2019 (issued on 25th May 2020).},
journal = {The Journal of laryngology and otology},
volume = {134},
number = {8},
pages = {661-664},
pmid = {32613918},
issn = {1748-5460},
mesh = {Audiology/*methods/standards ; Betacoronavirus/*isolation & purification ; COVID-19 ; Child ; Child, Preschool ; Coronavirus Infections/epidemiology/*prevention & control/virology ; Deglutition Disorders/diagnosis/surgery/virology ; Europe/epidemiology ; Humans ; Mandatory Testing/standards ; Otolaryngology/*methods/standards ; Pandemics/*prevention & control ; Pediatrics/standards ; Personal Protective Equipment/standards/supply & distribution ; Pneumonia, Viral/epidemiology/*prevention & control/virology ; Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical/organization & administration ; Voice Disorders/diagnosis/surgery/virology ; },
abstract = {BACKGROUND: The following position statement from the Union of the European Phoniatricians, updated on 25th May 2020 (superseding the previous statement issued on 21st April 2020), contains a series of recommendations for phoniatricians and ENT surgeons who provide and/or run voice, swallowing, speech and language, or paediatric audiology services.

OBJECTIVES: This material specifically aims to inform clinical practices in countries where clinics and operating theatres are reopening for elective work. It endeavours to present a current European view in relation to common procedures, many of which fall under the aegis of aerosol generating procedures.

CONCLUSION: As evidence continues to build, some of the recommended practices will undoubtedly evolve, but it is hoped that the updated position statement will offer clinicians precepts on safe clinical practice.},
}

Audiology/*methods/standards
Betacoronavirus/*isolation & purification
COVID-19
Child
Child, Preschool
Coronavirus Infections/epidemiology/*prevention & control/virology
Deglutition Disorders/diagnosis/surgery/virology
Europe/epidemiology
Humans
Mandatory Testing/standards
Otolaryngology/*methods/standards
Pandemics/*prevention & control
Pediatrics/standards
Personal Protective Equipment/standards/supply & distribution
Pneumonia, Viral/epidemiology/*prevention & control/virology
Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical/organization & administration
Voice Disorders/diagnosis/surgery/virology

@article {pmid32601022,
year = {2020},
author = {Parsonage, WA and Cullen, L and Brieger, D and Hillis, GS and Nasis, A and Dwyer, N and Wahi, S and Lo, S and Than, M and Kerr, A and Devlin, G and Chew, DK},
title = {CSANZ Position Statement on the Evaluation of Patients Presenting With Suspected Acute Coronary Syndromes During the COVID-19 Pandemic.},
journal = {Heart, lung & circulation},
volume = {29},
number = {7},
pages = {e105-e110},
pmid = {32601022},
issn = {1444-2892},
mesh = {*Acute Coronary Syndrome/diagnosis/epidemiology/therapy ; Australia/epidemiology ; Betacoronavirus ; COVID-19 ; *Cardiology/methods/organization & administration/trends ; *Communicable Disease Control/methods/organization & administration ; Consensus ; *Coronavirus Infections/epidemiology/prevention & control ; Humans ; Infection Control/*organization & administration ; New Zealand/epidemiology ; *Pandemics/prevention & control ; Patient Care Management/*methods ; *Pneumonia, Viral/epidemiology/prevention & control ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {A pandemic of Coronavirus-19 disease was declared by the World Health Organization on March 11, 2020. The pandemic is expected to place unprecedented demand on health service delivery. This position statement has been developed by the Cardiac Society of Australia and New Zealand to assist clinicians to continue to deliver rapid and safe evaluation of patients presenting with suspected acute cardiac syndrome at this time. The position statement complements, and should be read in conjunction with, the National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016: Section 2 'Assessment of Possible Cardiac Chest Pain'.},
}

*Acute Coronary Syndrome/diagnosis/epidemiology/therapy
Australia/epidemiology
Betacoronavirus
COVID-19
*Cardiology/methods/organization & administration/trends
*Communicable Disease Control/methods/organization & administration
Consensus
*Coronavirus Infections/epidemiology/prevention & control
Humans
Infection Control/*organization & administration
New Zealand/epidemiology
*Pandemics/prevention & control
Patient Care Management/*methods
*Pneumonia, Viral/epidemiology/prevention & control
SARS-CoV-2
Societies, Medical

@article {pmid32574446,
year = {2020},
author = {},
title = {UHMS Position Statement: Hyperbaric Oxygen (HBO2) for COVID-19 Patients.},
journal = {Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc},
volume = {47},
number = {2},
pages = {297-298},
pmid = {32574446},
issn = {1066-2936},
mesh = {*Betacoronavirus ; COVID-19 ; Clinical Trials as Topic ; Coronavirus Infections/complications/*therapy ; Humans ; *Hyperbaric Oxygenation/adverse effects/methods ; Hypoxia/etiology/therapy ; Pandemics ; Pneumonia/etiology/therapy ; Pneumonia, Viral/complications/*therapy ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {There have been numerous recent inquiries regarding use of hyperbaric oxygen (HBO2) for patients with COVID-19. Questions have been raised pertinent to two possible mechanisms for HBO2 in this clinical context. The UHMS Hyperbaric Oxygen Therapy Committee, UHMS Executive Committee, with collaborative input from multiple senior UHMS members and researchers have drafted this position statement.},
}

*Betacoronavirus
COVID-19
Clinical Trials as Topic
Coronavirus Infections/complications/*therapy
Humans
*Hyperbaric Oxygenation/adverse effects/methods
Hypoxia/etiology/therapy
Pandemics
Pneumonia/etiology/therapy
Pneumonia, Viral/complications/*therapy
SARS-CoV-2
Societies, Medical

@article {pmid32548994,
year = {2020},
author = {Mureddu, GF and Ambrosetti, M and Venturini, E and La Rovere, MT and Mazza, A and Pedretti, R and Sarullo, F and Fattirolli, F and Faggiano, P and Giallauria, F and Vigorito, C and Angelino, E and Brazzo, S and Ruzzolini, M},
title = {Cardiac rehabilitation activities during the COVID-19 pandemic in Italy. Position Paper of the AICPR (Italian Association of Clinical Cardiology, Prevention and Rehabilitation).},
journal = {Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace},
volume = {90},
number = {2},
pages = {},
doi = {10.4081/monaldi.2020.1439},
pmid = {32548994},
issn = {2532-5264},
mesh = {Acute Coronary Syndrome/rehabilitation ; COVID-19 ; Cardiac Rehabilitation/psychology/*standards ; Cardiotonic Agents/adverse effects/therapeutic use ; Coronavirus Infections/*epidemiology ; Exercise ; Female ; Heart Failure/rehabilitation ; Humans ; Italy/epidemiology ; Male ; Nutrition Therapy ; Pandemics ; Pneumonia, Viral/*epidemiology ; Thromboembolism/rehabilitation ; },
abstract = {The COVID-19 outbreak is having a significant impact on both cardiac rehabilitation (CR) inpatient and outpatient healthcare organization. The variety of clinical and care scenarios we are observing in Italy depends on the region, the organization of local services and the hospital involved. Some hospital wards have been closed to make room to dedicated beds or to quarantine the exposed health personnel. In other cases, CR units have been converted or transformed into COVID-19 units. The present document aims at defining the state of the art of CR during COVID-19 pandemic, through the description of the clinical and management scenarios frequently observed during this period and the exploration of the future frontiers in the management of cardiac rehabilitation programs after the COVID-19 outbreak.},
}

Acute Coronary Syndrome/rehabilitation
COVID-19
Cardiac Rehabilitation/psychology/*standards
Cardiotonic Agents/adverse effects/therapeutic use
Coronavirus Infections/*epidemiology
Exercise
Female
Heart Failure/rehabilitation
Humans
Italy/epidemiology
Male
Nutrition Therapy
Pandemics
Pneumonia, Viral/*epidemiology
Thromboembolism/rehabilitation

@article {pmid32541561,
year = {2020},
author = {Zidan, A and Alabbad, S and Ali, T and Nizami, I and Haberal, M and Tokat, Y and Kamel, R and Said, H and Abdelaal, A and Elsharkawy, M and El Fouly, A and Sayed, H and Al-Mousawi, M and AlGhonaim, M and Broering, D},
title = {Position Statement of Transplant Activity in the Middle East in Era of COVID-19 Pandemic.},
journal = {Transplantation},
volume = {104},
number = {11},
pages = {2205-2207},
pmid = {32541561},
issn = {1534-6080},
mesh = {Betacoronavirus ; COVID-19 ; Coronavirus Infections/*epidemiology ; Delivery of Health Care/*standards ; Humans ; Middle East ; Organ Transplantation/statistics & numerical data/*trends ; Pandemics ; Pneumonia, Viral/*epidemiology ; SARS-CoV-2 ; },
}

Betacoronavirus
COVID-19
Coronavirus Infections/*epidemiology
Delivery of Health Care/*standards
Humans
Middle East
Organ Transplantation/statistics & numerical data/*trends
Pandemics
Pneumonia, Viral/*epidemiology
SARS-CoV-2

@article {pmid32537929,
year = {2020},
author = {Hamad, N and Gottlieb, D and Ritchie, D and Kennedy, G and Watson, AM and Greenwood, M and Doocey, R and Perera, T and Spencer, A and Wong, E and O'Brien, T and Shaw, P and Conyers, R and Cole, T and Milliken, S and Bardy, P and Larsen, S and Lai, H and Butler, A and Fraser, C and Bajel, A and Butler, J and Kerridge, I and Purtill, D},
title = {Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement.},
journal = {Internal medicine journal},
volume = {50},
number = {6},
pages = {774-775},
doi = {10.1111/imj.14867},
pmid = {32537929},
issn = {1445-5994},
mesh = {Australia ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques/*methods/statistics & numerical data ; Comorbidity ; *Consensus ; Coronavirus Infections/*diagnosis/physiopathology/therapy/virology ; Cryopreservation ; Hematopoietic Stem Cell Transplantation/*methods ; Humans ; Leukemia/physiopathology/*therapy ; New Zealand ; Pandemics ; Pneumonia, Viral/*diagnosis/physiopathology/therapy/virology ; Practice Guidelines as Topic ; Triage ; },
}

Australia
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques/*methods/statistics & numerical data
Comorbidity
*Consensus
Coronavirus Infections/*diagnosis/physiopathology/therapy/virology
Cryopreservation
Hematopoietic Stem Cell Transplantation/*methods
Humans
Leukemia/physiopathology/*therapy
New Zealand
Pandemics
Pneumonia, Viral/*diagnosis/physiopathology/therapy/virology
Practice Guidelines as Topic
Triage

@article {pmid32531110,
year = {2021},
author = {Pfaar, O and Klimek, L and Jutel, M and Akdis, CA and Bousquet, J and Breiteneder, H and Chinthrajah, S and Diamant, Z and Eiwegger, T and Fokkens, WJ and Fritsch, HW and Nadeau, KC and O'Hehir, RE and O'Mahony, L and Rief, W and Sampath, V and Schedlowski, M and Torres, MJ and Traidl-Hoffmann, C and Wang, Y and Zhang, L and Bonini, M and Brehler, R and Brough, HA and Chivato, T and Del Giacco, SR and Dramburg, S and Gawlik, R and Gelincik, A and Hoffmann-Sommergruber, K and Hox, V and Knol, EF and Lauerma, A and Matricardi, PM and Mortz, CG and Ollert, M and Palomares, O and Riggioni, C and Schwarze, J and Skypala, I and Untersmayr, E and Walusiak-Skorupa, J and Ansotegui, IJ and Bachert, C and Bedbrook, A and Bosnic-Anticevich, S and Brussino, L and Canonica, GW and Cardona, V and Carreiro-Martins, P and Cruz, AA and Czarlewski, W and Fonseca, JA and Gotua, M and Haahtela, T and Ivancevich, JC and Kuna, P and Kvedariene, V and Larenas-Linnemann, DE and Abdul Latiff, AH and Mäkelä, M and Morais-Almeida, M and Mullol, J and Naclerio, R and Ohta, K and Okamoto, Y and Onorato, GL and Papadopoulos, NG and Patella, V and Regateiro, FS and Samoliński, B and Suppli Ulrik, C and Toppila-Salmi, S and Valiulis, A and Ventura, MT and Yorgancioglu, A and Zuberbier, T and Agache, I},
title = {COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.},
journal = {Allergy},
volume = {76},
number = {3},
pages = {648-676},
pmid = {32531110},
issn = {1398-9995},
mesh = {Allergists ; COVID-19/*epidemiology/prevention & control ; Health Personnel ; Humans ; Hypersensitivity/diagnosis/*therapy ; Information Technology ; Patient Care Team ; *SARS-CoV-2 ; Triage ; },
abstract = {BACKGROUND: The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics.

METHOD: The scientific information on COVID-19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet.

RESULTS: Based on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID-19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the "Allergic Rhinitis and its Impact on Asthma (ARIA)" initiative have developed recommendations for the optimal management of allergy clinics during the current COVID-19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies.

CONCLUSIONS: This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID-19 pandemic.},
}

Allergists
COVID-19/*epidemiology/prevention & control
Health Personnel
Humans
Hypersensitivity/diagnosis/*therapy
Information Technology
Patient Care Team
*SARS-CoV-2
Triage

@article {pmid32513287,
year = {2020},
author = {Campanile, FC and Podda, M and Arezzo, A and Botteri, E and Sartori, A and Guerrieri, M and Cassinotti, E and Muttillo, I and Pisano, M and Brachet Contul, R and D'Ambrosio, G and Cuccurullo, D and Bergamini, C and Allaix, ME and Caracino, V and Petz, WL and Milone, M and Silecchia, G and Anania, G and Agrusa, A and Di Saverio, S and Casarano, S and Cicala, C and Narilli, P and Federici, S and Carlini, M and Paganini, A and Bianchi, PP and Salaj, A and Mazzari, A and Meniconi, RL and Puzziello, A and Terrosu, G and De Simone, B and Coccolini, F and Catena, F and Agresta, F},
title = {Acute cholecystitis during COVID-19 pandemic: a multisocietary position statement.},
journal = {World journal of emergency surgery : WJES},
volume = {15},
number = {1},
pages = {38},
pmid = {32513287},
issn = {1749-7922},
mesh = {Betacoronavirus ; COVID-19 ; Cholecystectomy/methods/*standards ; Cholecystitis, Acute/*surgery/virology ; Coronavirus Infections/*complications/virology ; Humans ; Infection Control/*standards ; Pandemics ; Pneumonia, Viral/*complications/virology ; *Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {Following the spread of the infection from the new SARS-CoV2 coronavirus in March 2020, several surgical societies have released their recommendations to manage the implications of the COVID-19 pandemic for the daily clinical practice. The recommendations on emergency surgery have fueled a debate among surgeons on an international level.We maintain that laparoscopic cholecystectomy remains the treatment of choice for acute cholecystitis, even in the COVID-19 era. Moreover, since laparoscopic cholecystectomy is not more likely to spread the COVID-19 infection than open cholecystectomy, it must be organized in such a way as to be carried out safely even in the present situation, to guarantee the patient with the best outcomes that minimally invasive surgery has shown to have.},
}

Betacoronavirus
COVID-19
Cholecystectomy/methods/*standards
Cholecystitis, Acute/*surgery/virology
Coronavirus Infections/*complications/virology
Humans
Infection Control/*standards
Pandemics
Pneumonia, Viral/*complications/virology
*Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical

@article {pmid32501145,
year = {2020},
author = {Linnemann, B and Bauersachs, R and Grebe, M and Klamroth, R and Müller, O and Schellong, S and Lichtenberg, M},
title = {Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).},
journal = {VASA. Zeitschrift fur Gefasskrankheiten},
volume = {49},
number = {4},
pages = {259-263},
doi = {10.1024/0301-1526/a000885},
pmid = {32501145},
issn = {0301-1526},
mesh = {Anticoagulants/*administration & dosage ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/*complications ; Humans ; Pandemics ; Pneumonia, Viral/*complications ; SARS-CoV-2 ; *Venous Thromboembolism ; },
abstract = {As observed in other infections with a systemic inflammatory response, severe COVID-19 is associated with hypercoagulability and a prothrombotic state. Currently, there is growing evidence that pulmonary embolism and thrombosis contribute to adverse outcomes and increased mortality in critically ill patients with COVID-19. The optimal thromboprophylactic regimen for patients with COVID-19 is not known. Whereas pharmacologic thromboprophylaxis is generally recommended for all hospitalized COVID-19 patients, adequate dosing of anticoagulants remains a controversial issue. Therefore, we summarize current evidence from the available literature and, on behalf of the German Society of Angiology (DGA), we aim to provide advice to establish an improved and more uniform strategy for thromboprophylaxis in patients with COVID-19.},
}

Anticoagulants/*administration & dosage
Betacoronavirus
COVID-19
Coronavirus Infections/*complications
Humans
Pandemics
Pneumonia, Viral/*complications
SARS-CoV-2
*Venous Thromboembolism

@article {pmid32500283,
year = {2020},
author = {Stolbach, AI and Mazer-Amirshahi, M and Marino, R and Nelson, LS and Sugarman, J},
title = {ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.},
journal = {Journal of medical toxicology : official journal of the American College of Medical Toxicology},
volume = {16},
number = {3},
pages = {342-345},
pmid = {32500283},
issn = {1937-6995},
mesh = {Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/*drug therapy ; Emergency Medical Services/*standards ; Humans ; Off-Label Use/*standards/*statistics & numerical data ; Pandemics ; Pneumonia, Viral/*drug therapy ; *Practice Guidelines as Topic ; SARS-CoV-2 ; United States ; United States Food and Drug Administration ; },
}

Betacoronavirus/drug effects
COVID-19
Coronavirus Infections/*drug therapy
Emergency Medical Services/*standards
Humans
Off-Label Use/*standards/*statistics & numerical data
Pandemics
Pneumonia, Viral/*drug therapy
*Practice Guidelines as Topic
SARS-CoV-2
United States
United States Food and Drug Administration

@article {pmid32489251,
year = {2020},
author = {Ahmed, S and Barbera, L and Bartlett, SJ and Bebb, DG and Brundage, M and Bryan, S and Cheung, WY and Coburn, N and Crump, T and Cuthbertson, L and Howell, D and Klassen, AF and Leduc, S and Li, M and Mayo, NE and McKinnon, G and Olson, R and Pink, J and Robinson, JW and Santana, MJ and Sawatzky, R and Moxam, RS and Sinclair, S and Servidio-Italiano, F and Temple, W},
title = {A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes.},
journal = {Current oncology (Toronto, Ont.)},
volume = {27},
number = {2},
pages = {90-99},
pmid = {32489251},
issn = {1718-7729},
mesh = {Canada ; Delivery of Health Care/methods/standards/*statistics & numerical data ; Humans ; Medical Oncology/methods/standards/*statistics & numerical data ; Neoplasms/diagnosis/*therapy ; *Patient Reported Outcome Measures ; Patient-Centered Care/methods/standards/*statistics & numerical data ; Quality of Life ; },
abstract = {BACKGROUND: Patient-reported outcomes (pros) are essential to capture the patient's perspective and to influence care. Although pros and pro measures are known to have many important benefits, they are not consistently being used and there is there no Canadian pros oversight. The Position Statement presented here is the first step toward supporting the implementation of pros in the Canadian health care setting.

METHODS: The Canadian pros National Steering Committee drafted position statements, which were submitted for stakeholder feedback before, during, and after the first National Canadian Patient Reported Outcomes (canpros) scientific conference, 14-15 November 2019 in Calgary, Alberta. In addition to the stakeholder feedback cycle, a patient advocate group submitted a section to capture the patient voice.

RESULTS: The canpros Position Statement is an outcome of the 2019 canpros scientific conference, with an oncology focus. The Position Statement is categorized into 6 sections covering 4 theme areas: Patient and Families, Health Policy, Clinical Implementation, and Research. The patient voice perfectly mirrors the recommendations that the experts reached by consensus and provides an overriding impetus for the use of pros in health care.

CONCLUSIONS: Although our vision of pros transforming the health care system to be more patient-centred is still aspirational, the Position Statement presented here takes a first step toward providing recommendations in key areas to align Canadian efforts. The Position Statement is directed toward a health policy audience; future iterations will target other audiences, including researchers, clinicians, and patients. Our intent is that future versions will broaden the focus to include chronic diseases beyond cancer.},
}

Canada
Delivery of Health Care/methods/standards/*statistics & numerical data
Humans
Medical Oncology/methods/standards/*statistics & numerical data
Neoplasms/diagnosis/*therapy
*Patient Reported Outcome Measures
Patient-Centered Care/methods/standards/*statistics & numerical data
Quality of Life

@article {pmid32487434,
year = {2020},
author = {Lal, S and Van Gossum, A and Joly, F and Bozzetti, F and Cuerda, C and Lamprecht, G and Mundi, MS and Staun, M and Szczepanek, K and Wanten, G and Wheatley, C and Pironi, L and , },
title = {Considerations for the management of home parenteral nutrition during the SARS-CoV-2 pandemic: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN.},
journal = {Clinical nutrition (Edinburgh, Scotland)},
volume = {39},
number = {7},
pages = {1988-1991},
pmid = {32487434},
issn = {1532-1983},
mesh = {Betacoronavirus ; COVID-19 ; Chronic Disease ; *Coronavirus Infections/complications/therapy ; Hospitalization ; Humans ; *Intestinal Diseases/complications/therapy ; *Pandemics ; *Parenteral Nutrition, Home ; *Pneumonia, Viral/complications/therapy ; Practice Guidelines as Topic ; SARS-CoV-2 ; },
abstract = {The management of patients with chronic intestinal failure requiring home parenteral nutrition has been and will continue to be impaired during the SARS-CoV-2 pandemic. Multidisciplinary intestinal failure teams may have to adapt their clinical approaches to home care, outpatient care as well as hospital admission and discharge in order to keep this vulnerable group of patients as safe and well as possible during the unprecedented challenges that countries are facing during the pandemic. Equally, it is important that expert advice from intestinal failure teams is available when home parenteral nutrition (HPN)-dependent patients require admission with SARS-CoV-2 infection. The Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of the European Society for Clinical Nutrition and Metabolism (ESPEN) has developed a position paper to outline areas for intestinal failure teams to consider when managing patients with chronic intestinal failure during the SARS-CoV-2 pandemic.},
}

Betacoronavirus
COVID-19
Chronic Disease
*Coronavirus Infections/complications/therapy
Hospitalization
Humans
*Intestinal Diseases/complications/therapy
*Pandemics
*Parenteral Nutrition, Home
*Pneumonia, Viral/complications/therapy
Practice Guidelines as Topic
SARS-CoV-2

@article {pmid32473781,
year = {2020},
author = {Nicholls, SJ and Nelson, M and Astley, C and Briffa, T and Brown, A and Clark, R and Colquhoun, D and Gallagher, R and Hare, DL and Inglis, S and Jelinek, M and O'Neil, A and Tirimacco, R and Vale, M and Redfern, J},
title = {Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement From the Cardiac Society of Australia and New Zealand (CSANZ).},
journal = {Heart, lung & circulation},
volume = {29},
number = {7},
pages = {e99-e104},
pmid = {32473781},
issn = {1444-2892},
mesh = {Australia/epidemiology ; Betacoronavirus ; COVID-19 ; *Cardiac Rehabilitation/methods/trends ; *Cardiology/methods/organization & administration/trends ; *Cardiovascular Diseases/complications/epidemiology/prevention & control ; Consensus ; *Coronavirus Infections/epidemiology/prevention & control ; Delivery of Health Care/organization & administration ; Humans ; Infection Control/*organization & administration ; New Zealand/epidemiology ; *Pandemics/prevention & control ; *Pneumonia, Viral/epidemiology/prevention & control ; SARS-CoV-2 ; *Secondary Prevention/methods/organization & administration ; Societies, Medical ; },
abstract = {BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has introduced a major disruption to the delivery of routine health care across the world. This provides challenges for the use of secondary prevention measures in patients with established atherosclerotic cardiovascular disease (CVD). The aim of this Position Statement is to review the implications for effective delivery of secondary prevention strategies during the COVID-19 pandemic.

CHALLENGES: The COVID-19 pandemic has introduced limitations for many patients to access standard health services such as visits to health care professionals, medications, imaging and blood tests as well as attendance at cardiac rehabilitation. In addition, the pandemic is having an impact on lifestyle habits and mental health. Taken together, this has the potential to adversely impact the ability of practitioners and patients to adhere to treatment guidelines for the prevention of recurrent cardiovascular events.

RECOMMENDATIONS: Every effort should be made to deliver safe, ongoing access to health care professionals and the use of evidenced based therapies in individuals with CVD. An increase in use of a range of electronic health platforms has the potential to transform secondary prevention. Integrating research programs that evaluate the utility of these approaches may provide important insights into how to develop more optimal approaches to secondary prevention beyond the pandemic.},
}

Australia/epidemiology
Betacoronavirus
COVID-19
*Cardiac Rehabilitation/methods/trends
*Cardiology/methods/organization & administration/trends
*Cardiovascular Diseases/complications/epidemiology/prevention & control
Consensus
*Coronavirus Infections/epidemiology/prevention & control
Delivery of Health Care/organization & administration
Humans
Infection Control/*organization & administration
New Zealand/epidemiology
*Pandemics/prevention & control
*Pneumonia, Viral/epidemiology/prevention & control
SARS-CoV-2
*Secondary Prevention/methods/organization & administration
Societies, Medical

@article {pmid32467031,
year = {2020},
author = {Wahi, S and Thomas, L and Stanton, T and Taylor, A and Mahadevan, D and Evans, G and Playford, D and To, A and Davis, M and Anderson, B and Buckley, B},
title = {CSANZ Imaging Council Position Statement on Echocardiography Services During the COVID-19 Pandemic.},
journal = {Heart, lung & circulation},
volume = {29},
number = {6},
pages = {e78-e83},
pmid = {32467031},
issn = {1444-2892},
mesh = {Australia/epidemiology ; *Betacoronavirus ; COVID-19 ; Cardiology ; *Coronavirus Infections/diagnostic imaging/epidemiology ; Delivery of Health Care/*standards ; Echocardiography/*standards ; Humans ; New Zealand/epidemiology ; *Pandemics ; *Pneumonia, Viral/diagnostic imaging/epidemiology ; Positron-Emission Tomography/*standards ; Risk Assessment ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {This Cardiac Society of Australia and New Zealand (CSANZ) Imaging Council Position Statement aims to guide local, regional and national clinical practice, and facilitate resource and echocardiographic service planning appropriately during the current COVID-19 global pandemic. General considerations include workforce arrangements and contingency plans, patient risk assessment for COVID-19 and level of care (personal protective equipment) for staff. Both outpatient and inpatient settings are addressed, including specific considerations in the in-patient setting including scanning protocols, screening modalities and indications for echocardiograms in the context of COVID-19 infection.},
}

Australia/epidemiology
*Betacoronavirus
COVID-19
Cardiology
*Coronavirus Infections/diagnostic imaging/epidemiology
Delivery of Health Care/*standards
Echocardiography/*standards
Humans
New Zealand/epidemiology
*Pandemics
*Pneumonia, Viral/diagnostic imaging/epidemiology
Positron-Emission Tomography/*standards
Risk Assessment
SARS-CoV-2
Societies, Medical

@article {pmid32451232,
year = {2020},
author = {Kumar, S and Haqqani, H and Wynn, G and Pathak, RK and Lipton, J and Mahajan, R and Sanders, P and Healey, S and Wilsmore, B and Mariani, JA and Thomas, SP and Weerasooriya, R and McGavigan, A and Gould, PA and Weatherley, P and Saad, N and Cowan, M and Turnbull, S and Trivic, I and Wong, M and Tonchev, I and Morton, JB and Skinner, JR and Pflaumer, A and McGuire, M and Kistler, P and Kalman, JM and , },
title = {Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia During the COVID-19 Pandemic: A Living Document.},
journal = {Heart, lung & circulation},
volume = {29},
number = {6},
pages = {e57-e68},
pmid = {32451232},
issn = {1444-2892},
mesh = {Australia/epidemiology ; *Betacoronavirus ; COVID-19 ; *Coronavirus Infections/epidemiology/physiopathology/therapy ; *Defibrillators, Implantable ; *Electrophysiologic Techniques, Cardiac ; Humans ; *Pandemics ; *Pneumonia, Viral/epidemiology/physiopathology/therapy ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic poses a significant stress on health resources in Australia. The Heart Rhythm Council of the Cardiac Society of Australia and New Zealand aims to provide a framework for efficient resource utilisation balanced with competing risks when appropriately treating patients with cardiac arrhythmias. This document provides practical recommendations for the electrophysiology (EP) and cardiac implantable electronic devices (CIED) services in Australia. The document will be updated regularly as new evidence and knowledge is gained with time.},
}

Australia/epidemiology
*Betacoronavirus
COVID-19
*Coronavirus Infections/epidemiology/physiopathology/therapy
*Defibrillators, Implantable
*Electrophysiologic Techniques, Cardiac
Humans
*Pandemics
*Pneumonia, Viral/epidemiology/physiopathology/therapy
SARS-CoV-2

@article {pmid32425181,
year = {2020},
author = {Bonalumi, G and Di Mauro, M and Garatti, A and Barili, F and Parolari, A and Gerosa, G},
title = {[COVID-19 outbreak and Cardiac Surgery: position paper from the COVID-SICCH Task Force of the Italian Society for Cardiac Surgery].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {21},
number = {6},
pages = {396-400},
doi = {10.1714/3359.33320},
pmid = {32425181},
issn = {1972-6481},
mesh = {COVID-19 ; Cardiovascular Surgical Procedures/methods/*standards ; Coronavirus Infections/*complications ; Humans ; Italy ; Pandemics ; Pneumonia, Viral/*complications ; *Practice Guidelines as Topic ; Risk Assessment ; Societies, Medical ; },
}

COVID-19
Cardiovascular Surgical Procedures/methods/*standards
Coronavirus Infections/*complications
Humans
Italy
Pandemics
Pneumonia, Viral/*complications
*Practice Guidelines as Topic
Risk Assessment
Societies, Medical

@article {pmid32418875,
year = {2020},
author = {Lal, S and Hayward, CS and De Pasquale, C and Kaye, D and Javorsky, G and Bergin, P and Atherton, JJ and Ilton, MK and Weintraub, RG and Nair, P and Rudas, M and Dembo, L and Doughty, RN and Kumarasinghe, G and Juergens, C and Bannon, PG and Bart, NK and Chow, CK and Lattimore, JD and Kritharides, L and Totaro, R and Macdonald, PS},
title = {COVID-19 and Acute Heart Failure: Screening the Critically Ill - A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ).},
journal = {Heart, lung & circulation},
volume = {29},
number = {7},
pages = {e94-e98},
pmid = {32418875},
issn = {1444-2892},
mesh = {Australia/epidemiology ; Betacoronavirus ; COVID-19 ; *Cardiology/methods/organization & administration/trends ; Consensus ; *Coronavirus Infections/epidemiology/prevention & control ; Critical Illness/therapy ; *Heart Failure/diagnosis/etiology/therapy ; Humans ; *Infection Control/methods/organization & administration ; *Myocarditis/complications/virology ; New Zealand/epidemiology ; *Pandemics/prevention & control ; Patient Care Management/*methods ; *Pneumonia, Viral/epidemiology/prevention & control ; Risk Adjustment/methods ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {Up to one-third of COVID-19 patients admitted to intensive care develop an acute cardiomyopathy, which may represent myocarditis or stress cardiomyopathy. Further, while mortality in older patients with COVID-19 appears related to multi-organ failure complicating acute respiratory distress syndrome (ARDS), the cause of death in younger patients may be related to acute heart failure. Cardiac involvement needs to be considered early on in critically ill COVID-19 patients, and even after the acute respiratory phase is passing. This Statement presents a screening algorithm to better identify COVID-19 patients at risk for severe heart failure and circulatory collapse, while balancing the need to protect health care workers and preserve personal protective equipment (PPE). The significance of serum troponin levels and the role of telemetry and targeted transthoracic echocardiography (TTE) in patient investigation and management are addressed, as are fundamental considerations in the management of acute heart failure in COVID-19 patients.},
}

Australia/epidemiology
Betacoronavirus
COVID-19
*Cardiology/methods/organization & administration/trends
Consensus
*Coronavirus Infections/epidemiology/prevention & control
Critical Illness/therapy
*Heart Failure/diagnosis/etiology/therapy
Humans
*Infection Control/methods/organization & administration
*Myocarditis/complications/virology
New Zealand/epidemiology
*Pandemics/prevention & control
Patient Care Management/*methods
*Pneumonia, Viral/epidemiology/prevention & control
Risk Adjustment/methods
SARS-CoV-2
Societies, Medical

@article {pmid32418120,
year = {2020},
author = {Mazer-Amirshahi, M and Fox, ER and Farmer, BM and Stolbach, AI},
title = {ACMT Position Statement: Medication Shortages During Coronavirus Disease Pandemic.},
journal = {Journal of medical toxicology : official journal of the American College of Medical Toxicology},
volume = {16},
number = {3},
pages = {346-348},
pmid = {32418120},
issn = {1937-6995},
mesh = {Antiviral Agents/*supply & distribution/*therapeutic use ; Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/*drug therapy ; Humans ; Medication Systems, Hospital/*standards/*statistics & numerical data ; Pandemics ; Pneumonia, Viral/*drug therapy ; *Practice Guidelines as Topic ; SARS-CoV-2 ; },
}

Antiviral Agents/*supply & distribution/*therapeutic use
Betacoronavirus/drug effects
COVID-19
Coronavirus Infections/*drug therapy
Humans
Medication Systems, Hospital/*standards/*statistics & numerical data
Pandemics
Pneumonia, Viral/*drug therapy
*Practice Guidelines as Topic
SARS-CoV-2

@article {pmid32414880,
year = {2020},
author = {Rubin, MA and Bonnie, RJ and Epstein, L and Hemphill, C and Kirschen, M and Lewis, A and Suarez, JI and , },
title = {AAN position statement: The COVID-19 pandemic and the ethical duties of the neurologist.},
journal = {Neurology},
volume = {95},
number = {4},
pages = {167-172},
doi = {10.1212/WNL.0000000000009744},
pmid = {32414880},
issn = {1526-632X},
mesh = {COVID-19 ; Coronavirus Infections/complications/*therapy ; Health Resources ; Humans ; Nervous System Diseases/complications ; Neurologists/*ethics ; Neurology/education/*ethics ; Pandemics/*ethics ; Pneumonia, Viral/complications/*therapy ; Referral and Consultation ; Societies, Medical ; Telemedicine ; },
abstract = {Patients, clinicians, and hospitals have undergone monumental changes during the coronavirus disease 2019 (COVID-19) pandemic. This crisis has forced us to consider the obligations that we neurologists have to our individual patients as well as the greater community. By returning to our fundamental understanding of these duties, we can ensure that we are providing the most ethically appropriate contingency and crisis care possible. We recommend specific adaptations to both the inpatient and outpatient settings, as well as changes to medical and trainee education. Furthermore, we explore the daunting but potentially necessary implementation of scare resource allocation protocols. As the pandemic evolves, we will need to adapt continuously to these rapidly changing circumstances and consider both national and regional standards and variation.},
}

COVID-19
Coronavirus Infections/complications/*therapy
Health Resources
Humans
Nervous System Diseases/complications
Neurologists/*ethics
Neurology/education/*ethics
Pandemics/*ethics
Pneumonia, Viral/complications/*therapy
Referral and Consultation
Societies, Medical
Telemedicine

@article {pmid32404302,
year = {2020},
author = {Chieffo, A and Stefanini, GG and Price, S and Barbato, E and Tarantini, G and Karam, N and Moreno, R and Buchanan, GL and Gilard, M and Halvorsen, S and Huber, K and James, S and Neumann, FJ and Möllmann, H and Roffi, M and Tavazzi, G and Ferré, JM and Windecker, S and Dudek, D and Baumbach, A},
title = {EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic.},
journal = {EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology},
volume = {16},
number = {3},
pages = {233-246},
doi = {10.4244/EIJY20M05_01},
pmid = {32404302},
issn = {1969-6213},
mesh = {Acute Coronary Syndrome/*therapy ; Algorithms ; Betacoronavirus ; COVID-19 ; Cardiology/*standards ; *Coronavirus Infections ; Europe ; Humans ; *Pandemics ; *Pneumonia, Viral ; SARS-CoV-2 ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic poses an unprecedented challenge to healthcare worldwide. The infection can be life threatening and require intensive care treatment. The transmission of the disease poses a risk to both patients and healthcare workers. The number of patients requiring hospital admission and intensive care may overwhelm health systems and negatively affect standard care for patients presenting with conditions needing emergency interventions. This position statements aims to assist cardiologists in the invasive management of acute coronary syndrome (ACS) patients in the context of the COVID-19 pandemic. To that end, we assembled a panel of interventional cardiologists and acute cardiac care specialists appointed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and from the Acute Cardiovascular Care Association (ACVC) and included the experience from the first and worst affected areas in Europe. Modified diagnostic and treatment algorithms are proposed to adapt evidence-based protocols for this unprecedented challenge. Various clinical scenarios, as well as management algorithms for patients with a diagnosed or suspected COVID-19 infection, presenting with ST- and non-ST-segment elevation ACS are described. In addition, we address the need for re-organization of ACS networks, with redistribution of hub and spoke hospitals, as well as for in-hospital reorganization of emergency rooms and cardiac units, with examples coming from multiple European countries. Furthermore, we provide a guidance to reorganization of catheterization laboratories and, importantly, measures for protection of healthcare providers involved with invasive procedures.},
}

Acute Coronary Syndrome/*therapy
Algorithms
Betacoronavirus
COVID-19
Cardiology/*standards
*Coronavirus Infections
Europe
Humans
*Pandemics
*Pneumonia, Viral
SARS-CoV-2

@article {pmid32381517,
year = {2020},
author = {Klein, JD and Koletzko, B and El-Shabrawi, MH and Hadjipanayis, A and Thacker, N and Bhutta, Z},
title = {Promoting and supporting children's health and healthcare during COVID-19 - International Paediatric Association Position Statement.},
journal = {Archives of disease in childhood},
volume = {105},
number = {7},
pages = {620-624},
doi = {10.1136/archdischild-2020-319370},
pmid = {32381517},
issn = {1468-2044},
mesh = {Adolescent ; Betacoronavirus/*pathogenicity ; COVID-19 ; Child ; *Child Health ; Child, Preschool ; Consensus ; Coronavirus Infections/*prevention & control ; Health Promotion/*organization & administration ; Humans ; Infant ; Infant, Newborn ; Pandemics/*prevention & control ; *Pediatrics ; Pneumonia, Viral/*prevention & control ; Practice Guidelines as Topic ; *Public Health ; SARS-CoV-2 ; World Health Organization ; },
}

Adolescent
Betacoronavirus/*pathogenicity
COVID-19
Child
*Child Health
Child, Preschool
Consensus
Coronavirus Infections/*prevention & control
Health Promotion/*organization & administration
Humans
Infant
Infant, Newborn
Pandemics/*prevention & control
*Pediatrics
Pneumonia, Viral/*prevention & control
Practice Guidelines as Topic
*Public Health
SARS-CoV-2
World Health Organization

@article {pmid32374440,
year = {2020},
author = {Farrell, TW and Ferrante, LE and Brown, T and Francis, L and Widera, E and Rhodes, R and Rosen, T and Hwang, U and Witt, LJ and Thothala, N and Liu, SW and Vitale, CA and Braun, UK and Stephens, C and Saliba, D},
title = {AGS Position Statement: Resource Allocation Strategies and Age-Related Considerations in the COVID-19 Era and Beyond.},
journal = {Journal of the American Geriatrics Society},
volume = {68},
number = {6},
pages = {1136-1142},
pmid = {32374440},
issn = {1532-5415},
support = {K76 AG054862/AG/NIA NIH HHS/United States ; K76 AG054866/AG/NIA NIH HHS/United States ; K76 AG057023/AG/NIA NIH HHS/United States ; UL1 TR001863/TR/NCATS NIH HHS/United States ; },
mesh = {Aged ; Aged, 80 and over ; *Betacoronavirus ; COVID-19 ; *Coronavirus Infections ; Female ; Geriatrics/*standards ; Health Care Rationing/*standards ; *Health Planning Guidelines ; Humans ; Male ; *Pandemics ; *Pneumonia, Viral ; SARS-CoV-2 ; United States/epidemiology ; },
abstract = {Coronavirus disease 2019 (COVID-19) continues to impact older adults disproportionately, from severe illness and hospitalization to increased mortality risk. Concurrently, concerns about potential shortages of healthcare professionals and health supplies to address these needs have focused attention on how resources are ultimately allocated and used. Some strategies misguidedly use age as an arbitrary criterion, inappropriately disfavoring older adults. This statement represents the official policy position of the American Geriatrics Society (AGS). It is intended to inform stakeholders including hospitals, health systems, and policymakers about ethical considerations to consider when developing strategies for allocating scarce resources during an emergency involving older adults. Members of the AGS Ethics Committee collaborated with interprofessional experts in ethics, law, nursing, and medicine (including geriatrics, palliative care, emergency medicine, and pulmonology/critical care) to conduct a structured literature review and examine relevant reports. The resulting recommendations defend a particular view of distributive justice that maximizes relevant clinical factors and deemphasizes or eliminates factors placing arbitrary, disproportionate weight on advanced age. The AGS positions include (1) avoiding age per se as a means for excluding anyone from care; (2) assessing comorbidities and considering the disparate impact of social determinants of health; (3) encouraging decision makers to focus primarily on potential short-term (not long-term) outcomes; (4) avoiding ancillary criteria such as "life-years saved" and "long-term predicted life expectancy" that might disadvantage older people; (5) forming and staffing triage committees tasked with allocating scarce resources; (6) developing institutional resource allocation strategies that are transparent and applied uniformly; and (7) facilitating appropriate advance care planning. The statement includes recommendations that should be immediately implemented to address resource allocation strategies during COVID-19, aligning with AGS positions. The statement also includes recommendations for post-pandemic review. Such review would support revised strategies to ensure that governments and institutions have equitable emergency resource allocation strategies, avoid future discriminatory language and practice, and have appropriate guidance to develop national frameworks for emergent resource allocation decisions. J Am Geriatr Soc 68:1136-1142, 2020.},
}

Aged
Aged, 80 and over
*Betacoronavirus
COVID-19
*Coronavirus Infections
Female
Geriatrics/*standards
Health Care Rationing/*standards
*Health Planning Guidelines
Humans
Male
*Pandemics
*Pneumonia, Viral
SARS-CoV-2
United States/epidemiology

@article {pmid32371055,
year = {2020},
author = {Lavinsky, J and Kosugi, EM and Baptistella, E and Roithmann, R and Dolci, E and Ribeiro, TK and Rossini, B and Romano, FR and Maunsell, RCK and Mitre, EI and Imamura, R and Hachiya, A and Chone, CT and Watanabe, LMN and Fornazieri, MA and Lessa, MM and Sant'Anna, GD},
title = {An update on COVID-19 for the otorhinolaryngologist - a Brazilian Association of Otolaryngology and Cervicofacial Surgery (ABORL-CCF) Position Statement.},
journal = {Brazilian journal of otorhinolaryngology},
volume = {86},
number = {3},
pages = {273-280},
pmid = {32371055},
issn = {1808-8686},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/*prevention & control ; Humans ; Infectious Disease Transmission, Patient-to-Professional/prevention & control ; Otolaryngology/*standards ; Pandemics/*prevention & control ; Personal Protective Equipment/*standards ; Pneumonia, Viral/*prevention & control ; Practice Guidelines as Topic ; Practice Patterns, Physicians' ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {INTRODUCTION: We are facing a pandemic with a great impact worldwide, as a result of the rapid spread of the novel coronavirus (COVID-19). The medical community is still getting to know behavior of this virus and the consequences from a population point of view. All this knowledge is extremely dynamic, so some behaviors are still not well established. Otorhinolaryngologists have a central role in the management of this situation, in which they must assess the patient, avoid contamination to and by health professionals and other patients. Thus, the recommendations of the Brazilian Association of Otorhinolaryngology and Cervical-Facial Surgery (ABORL-CCF) have the main objective of reducing the spread of the new coronavirus during otorhinolaryngological care and assisting in the management of these patients.

METHODS: Review of the main recommendations of national and international scientific societies, decisions by government agencies and class councils. The topics will be related to the general aspects of COVID-19, personal protective equipment, care in patient assistance, endoscopic exam routines and the management of sinonasal, otological and pediatric evaluations related to COVID-19.

RESULTS: The use of personal protective equipment is considered crucial in routine ENT care. We recommend postponing appointments, exams and elective surgeries to reduce the spread of COVID-19. Similarly, we recommend changing routines in several areas of otolaryngology. Additionally, guidance is provided on the use of telemedicine resources during the pandemic period.

CONCLUSIONS: We are still at the beginning of the COVID-19 pandemic and scientific evidence is still scarce and incomplete, so these ABORL-CCF recommendations for otorhinolaryngologists may be updated based on new knowledge and the pattern of the new coronavirus spread.},
}

*Betacoronavirus
COVID-19
Coronavirus Infections/*prevention & control
Humans
Infectious Disease Transmission, Patient-to-Professional/prevention & control
Otolaryngology/*standards
Pandemics/*prevention & control
Personal Protective Equipment/*standards
Pneumonia, Viral/*prevention & control
Practice Guidelines as Topic
Practice Patterns, Physicians'
SARS-CoV-2
Societies, Medical

@article {pmid32323287,
year = {2020},
author = {Pfeifer, M and Ewig, S and Voshaar, T and Randerath, W and Bauer, T and Geiseler, J and Dellweg, D and Westhoff, M and Windisch, W and Schönhofer, B and Kluge, S and Lepper, PM},
title = {[Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19 - German Respiratory Society].},
journal = {Pneumologie (Stuttgart, Germany)},
volume = {74},
number = {6},
pages = {337-357},
pmid = {32323287},
issn = {1438-8790},
mesh = {Berlin ; Betacoronavirus ; COVID-19 ; *Continuous Positive Airway Pressure/standards ; Coronavirus Infections/complications/epidemiology ; Humans ; Intubation, Intratracheal ; Lung/physiopathology/virology ; Noninvasive Ventilation/*methods ; Pandemics ; Pneumonia, Viral/complications/epidemiology ; *Positive-Pressure Respiration ; *Practice Guidelines as Topic ; Pulmonary Edema/etiology/*therapy ; Respiratory Distress Syndrome/etiology/*therapy ; Respiratory Insufficiency/prevention & control/*therapy ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {Against the background of the pandemic caused by infection with the SARS-CoV-2, the German Society for Pneumology and Respiratory Medicine (DGP e.V.), in cooperation with other associations, has designated a team of experts in order to answer the currently pressing questions about therapy strategies in dealing with COVID-19 patients suffering from acute respiratory insufficiency (ARI).The position paper is based on the current knowledge that is evolving daily. Many of the published and cited studies require further review, also because many of them did not undergo standard review processes.Therefore, this position paper is also subject to a continuous review process and will be further developed in cooperation with the other professional societies.This position paper is structured into the following five topics:1. Pathophysiology of acute respiratory insufficiency in patients without immunity infected with SARS-CoV-22. Temporal course and prognosis of acute respiratory insufficiency during the course of the disease3. Oxygen insufflation, high-flow oxygen, non-invasive ventilation and invasive ventilation with special consideration of infectious aerosol formation4. Non-invasive ventilation in ARI5. Supply continuum for the treatment of ARIKey points have been highlighted as core statements and significant observations. Regarding the pathophysiological aspects of acute respiratory insufficiency (ARI), the pulmonary infection with SARS-CoV-2 COVID-19 runs through three phases: early infection, pulmonary manifestation and severe hyperinflammatory phase.There are differences between advanced COVID-19-induced lung damage and those changes seen in Acute Respiratory Distress Syndromes (ARDS) as defined by the Berlin criteria. In a pathophysiologically plausible - but currently not yet histopathologically substantiated - model, two types (L-type and H-type) are distinguished, which correspond to an early and late phase. This distinction can be taken into consideration in the differential instrumentation in the therapy of ARI.The assessment of the extent of ARI should be carried out by an arterial or capillary blood gas analysis under room air conditions and must include the calculation of the oxygen supply (measured from the variables of oxygen saturation, the Hb value, the corrected values of the Hüfner number and the cardiac output). In principle, aerosols can cause transmission of infectious viral particles. Open systems or leakage systems (so-called vented masks) can prevent the release of respirable particles. Procedures in which the invasive ventilation system must be opened, and endotracheal intubation must be carried out are associated with an increased risk of infection.The protection of personnel with personal protective equipment should have very high priority because fear of contagion must not be a primary reason for intubation. If the specifications for protective equipment (eye protection, FFP2 or FFP-3 mask, gown) are adhered to, inhalation therapy, nasal high-flow (NHF) therapy, CPAP therapy or NIV can be carried out according to the current state of knowledge without increased risk of infection to the staff. A significant proportion of patients with respiratory failure presents with relevant hypoxemia, often also caused by a high inspiratory oxygen fraction (FiO2) including NHF, and this hypoxemia cannot be not completely corrected. In this situation, CPAP/NIV therapy can be administered under use of a mouth and nose mask or a respiratory helmet as therapy escalation, as long as the criteria for endotracheal intubation are not fulfilled.In acute hypoxemic respiratory insufficiency, NIV should be performed in an intensive care unit or in a comparable unit by personnel with appropriate expertise. Under CPAP/NIV, a patient can deteriorate rapidly. For this reason, continuous monitoring with readiness to carry out intubation must be ensured at all times. If CPAP/NIV leads to further progression of ARI, intubation and subsequent invasive ventilation should be carried out without delay if no DNI order is in place.In the case of patients in whom invasive ventilation, after exhausting all guideline-based measures, is not sufficient, extracorporeal membrane oxygenation procedure (ECMO) should be considered to ensure sufficient oxygen supply and to remove CO2.},
}

Berlin
Betacoronavirus
COVID-19
*Continuous Positive Airway Pressure/standards
Coronavirus Infections/complications/epidemiology
Humans
Intubation, Intratracheal
Lung/physiopathology/virology
Noninvasive Ventilation/*methods
Pandemics
Pneumonia, Viral/complications/epidemiology
*Positive-Pressure Respiration
*Practice Guidelines as Topic
Pulmonary Edema/etiology/*therapy
Respiratory Distress Syndrome/etiology/*therapy
Respiratory Insufficiency/prevention & control/*therapy
SARS-CoV-2
Societies, Medical

@article {pmid32320138,
year = {2021},
author = {Sadeghipour, P and Talasaz, AH and Eslami, V and Geraiely, B and Vojdanparast, M and Sedaghat, M and Moosavi, AF and Alipour-Parsa, S and Aminian, B and Firouzi, A and Ghaffari, S and Ghasemi, M and Saleh, DK and Khosravi, A and Kojuri, J and Noohi, F and Pourhosseini, H and Salarifar, M and Salehi, MR and Sezavar, H and Shabestari, M and Soleimani, A and Tabarsi, P and Parsa, AFZ and Abdi, S},
title = {Management of ST-segment-elevation myocardial infarction during the coronavirus disease 2019 (COVID-19) outbreak: Iranian"247" National Committee's position paper on primary percutaneous coronary intervention.},
journal = {Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions},
volume = {97},
number = {3},
pages = {E346-E351},
pmid = {32320138},
issn = {1522-726X},
mesh = {Algorithms ; COVID-19/*epidemiology/*prevention & control/transmission ; Humans ; Infection Control/*organization & administration ; Iran/epidemiology ; *Percutaneous Coronary Intervention ; ST Elevation Myocardial Infarction/*therapy ; },
abstract = {World Health Organization has designated coronavirus disease 2019 (COVID-19) as a pandemic. During the past several weeks, a considerable burden has been imposed on the Iranian's healthcare system. The present document reviewed the latest evidence and expert opinion regarding the management of ST-segment-elevation myocardial infarction during the outbreak of COVID-19 and outlines a practical algorithm for it.},
}

Algorithms
COVID-19/*epidemiology/*prevention & control/transmission
Humans
Infection Control/*organization & administration
Iran/epidemiology
*Percutaneous Coronary Intervention
ST Elevation Myocardial Infarction/*therapy

@article {pmid32311380,
year = {2020},
author = {Maillard, JY and Bloomfield, SF and Courvalin, P and Essack, SY and Gandra, S and Gerba, CP and Rubino, JR and Scott, EA},
title = {Reducing antibiotic prescribing and addressing the global problem of antibiotic resistance by targeted hygiene in the home and everyday life settings: A position paper.},
journal = {American journal of infection control},
volume = {48},
number = {9},
pages = {1090-1099},
pmid = {32311380},
issn = {1527-3296},
mesh = {Anti-Bacterial Agents/*adverse effects ; Bacterial Infections/drug therapy ; *Drug Resistance, Bacterial ; Global Health/*standards ; Humans ; Hygiene/*standards ; Prescription Drug Overuse/*prevention & control ; Sanitation/standards ; },
abstract = {Antimicrobial resistance (AMR) continues to threaten global health. Although global and national AMR action plans are in place, infection prevention and control is primarily discussed in the context of health care facilities with home and everyday life settings barely addressed. As seen with the recent global SARS-CoV-2 pandemic, everyday hygiene measures can play an important role in containing the threat from infectious microorganisms. This position paper has been developed following a meeting of global experts in London, 2019. It presents evidence that home and community settings are important for infection transmission and also the acquisition and spread of AMR. It also demonstrates that the targeted hygiene approach offers a framework for maximizing protection against colonization and infections, thereby reducing antibiotic prescribing and minimizing selection pressure for the development of antibiotic resistance. If combined with the provision of clean water and sanitation, targeted hygiene can reduce the circulation of resistant bacteria in homes and communities, regardless of a country's Human Development Index (overall social and economic development). Achieving a reduction of AMR strains in health care settings requires a mirrored reduction in the community. The authors call upon national and international policy makers, health agencies, and health care professionals to further recognize the importance of targeted hygiene in the home and everyday life settings for preventing and controlling infection, in a unified quest to tackle AMR.},
}

Anti-Bacterial Agents/*adverse effects
Bacterial Infections/drug therapy
*Drug Resistance, Bacterial
Global Health/*standards
Humans
Hygiene/*standards
Prescription Drug Overuse/*prevention & control
Sanitation/standards

@article {pmid32243317,
year = {2020},
author = {Garcia-Castrillo, L and Petrino, R and Leach, R and Dodt, C and Behringer, W and Khoury, A and Sabbe, M},
title = {European Society For Emergency Medicine position paper on emergency medical systems' response to COVID-19.},
journal = {European journal of emergency medicine : official journal of the European Society for Emergency Medicine},
volume = {27},
number = {3},
pages = {174-177},
pmid = {32243317},
issn = {1473-5695},
mesh = {Betacoronavirus ; COVID-19 ; Coronavirus Infections/*diagnosis/*therapy ; Emergency Medicine/*standards ; Emergency Service, Hospital/*organization & administration ; Humans ; Infection Control ; Pandemics ; Patient Isolation ; Personal Protective Equipment/supply & distribution ; Pneumonia, Viral/*diagnosis/*therapy ; SARS-CoV-2 ; Triage ; },
abstract = {The 2019 novel coronavirus acute respiratory epidemic is creating a stressed situation in all the health systems of the affected countries. Emergency medical systems and specifically the emergency departments as the front line of the health systems are suffering from overload and severe working conditions, the risk of contagion and transmission of the health professionals adds a substantial burden to their daily work. Under the perspective of European Society For Emergency Medicine, the recommendations provided by the health authorities are reviewed focus on the emergency department's activity.},
}

Betacoronavirus
COVID-19
Coronavirus Infections/*diagnosis/*therapy
Emergency Medicine/*standards
Emergency Service, Hospital/*organization & administration
Humans
Infection Control
Pandemics
Patient Isolation
Personal Protective Equipment/supply & distribution
Pneumonia, Viral/*diagnosis/*therapy
SARS-CoV-2
Triage

@article {pmid32223063,
year = {2020},
author = {Tarantini, G and Fraccaro, C and Chieffo, A and Marchese, A and Tarantino, FF and Rigattieri, S and Limbruno, U and Mauro, C and La Manna, A and Castiglioni, B and Longoni, M and Berti, S and Greco, F and Musumeci, G and Esposito, G and , },
title = {Italian Society of Interventional Cardiology (GISE) position paper for Cath lab-specific preparedness recommendations for healthcare providers in case of suspected, probable or confirmed cases of COVID-19.},
journal = {Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions},
volume = {96},
number = {4},
pages = {839-843},
pmid = {32223063},
issn = {1522-726X},
mesh = {*Betacoronavirus ; COVID-19 ; *Cardiac Catheterization ; Clinical Protocols ; Coronavirus Infections/epidemiology/*prevention & control/transmission ; Humans ; Infection Control/*organization & administration ; Italy ; Pandemics/*prevention & control ; Pneumonia, Viral/epidemiology/*prevention & control/transmission ; Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {COVID-19 pandemic raised the issue to guarantee the proper level of care to patients with acute cardiovascular diseases and concomitant suspected or confirmed COVID-19 and, in the meantime safety and protection of healthcare providers. The aim of this position paper is to provide standards to healthcare facilities and healthcare providers on infection prevention and control measures during the management of suspected and confirmed cases of 2019-nCoV infection accessing in cath-lab. The document represents the view of the Italian Society of Interventional Cardiology (GISE), and it is based on recommendations from the main World and European Health Organizations (WHO, and ECDC) as well as from the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI).},
}

*Betacoronavirus
COVID-19
*Cardiac Catheterization
Clinical Protocols
Coronavirus Infections/epidemiology/*prevention & control/transmission
Humans
Infection Control/*organization & administration
Italy
Pandemics/*prevention & control
Pneumonia, Viral/epidemiology/*prevention & control/transmission
Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical

@article {pmid32207189,
year = {2020},
author = {Poon, LC and Abramowicz, JS and Dall'Asta, A and Sande, R and Ter Haar, G and Maršal, K and Brezinka, C and Miloro, P and Basseal, J and Westerway, SC and Abu-Rustum, RS and Lees, C},
title = {ISUOG Safety Committee Position Statement on safe performance of obstetric and gynecological scans and equipment cleaning in context of COVID-19.},
journal = {Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology},
volume = {55},
number = {5},
pages = {709-712},
doi = {10.1002/uog.22027},
pmid = {32207189},
issn = {1469-0705},
mesh = {*Betacoronavirus ; COVID-19 ; *Coronavirus Infections/prevention & control/transmission ; *Diagnostic Techniques, Obstetrical and Gynecological/standards ; Equipment Safety/*standards ; Female ; Genital Diseases, Female/diagnosis ; Humans ; *Hygiene/standards ; *Pandemics/prevention & control ; *Pneumonia, Viral/prevention & control/transmission ; Pregnancy ; SARS-CoV-2 ; Societies, Medical ; },
}

*Betacoronavirus
COVID-19
*Coronavirus Infections/prevention & control/transmission
*Diagnostic Techniques, Obstetrical and Gynecological/standards
Equipment Safety/*standards
Female
Genital Diseases, Female/diagnosis
Humans
*Hygiene/standards
*Pandemics/prevention & control
*Pneumonia, Viral/prevention & control/transmission
Pregnancy
SARS-CoV-2
Societies, Medical

@article {pmid41401760,
year = {2025},
author = {Blanco, J and Ferreras, M and Cosido, O},
title = {Predictive modeling of hospital emergency department demand using artificial intelligence: A systematic review.},
journal = {International journal of medical informatics},
volume = {207},
number = {},
pages = {106215},
doi = {10.1016/j.ijmedinf.2025.106215},
pmid = {41401760},
issn = {1872-8243},
abstract = {BACKGROUND: Accurately forecasting patient arrivals in hospital emergency departments (EDs) is critical for hospital capacity and planning and clinical decision-making. Artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has shown promising performance over traditional time series approaches. However, the extent to which these models are validated and generalizable remains uncertain.

OBJECTIVE: To systematically review the literature on predictive models for hospital ED demand forecasting, focusing on algorithms used, internal and external variables, validation strategies and limitations pre- and post-pandemic developments.

METHODS: A systematic literature review (SLR) was conducted following PRISMA guidelines. Five databases (PubMed, IEEE, Springer, ScienceDirect, ACM) were searched for peer-reviewed articles published between January 2019 and July 2025. Eligible studies applied predictive algorithms - excluding those focused on COVID-19 - to forecast ED visits. Extracted data included modeling approaches, feature types, evaluation metrics, and validation methods.

RESULTS: Eleven studies met the inclusion criteria. Classical models such as ARIMA and SARIMA remain in use, but ML (e.g., XGBoost, Random Forest) and DL (e.g., LSTM, CNN) showed higher predictive accuracy, especially with high-dimensional, nonlinear data. Incorporating external variables-such as weather (temperature, humidity, wind), air quality, and calendar events-consistently improved performance. Common metrics included Mean Absolute Error (MAE), Root Mean Squared Error (RMSE), and Mean Absolute Percentage Error (MAPE), with MAPE ranging from 3 % to 18 %. Few studies performed external validation, and only a minority employed explainable AI methods (e.g., SHAP) to address interpretability.

CONCLUSIONS: AI-based models offer strong potential for ED demand forecasting, particularly when integrating environmental and temporal features. However, limited external validation and lack of interpretability remain significant barriers to clinical adoption. Future research should prioritize multicenter validation, standardized evaluation, and explainable AI to support reliable, transparent, and scalable use in hospital emergency departments.},
}

@article {pmid41401413,
year = {2025},
author = {Miranda Quintero, J and Celis-Amórtegui, M and Arturo Rojas, MC and Mendoza Rosado, L and Grillo-Ardila, CF and Grillo-Ardila, EK and Ramírez-Mosquera, JJ and Lovera, LA and Ramírez-Mosquera, MJ},
title = {[Consenso de expertos en torno a la vacunación como estrategia de prevención primaria para la mujer que se encuentra en edad reproductiva, gestando o en la edad adulta].},
journal = {Revista colombiana de obstetricia y ginecologia},
volume = {76},
number = {2},
pages = {},
doi = {10.18597/rcog.4310},
pmid = {41401413},
issn = {2463-0225},
mesh = {Humans ; Female ; Pregnancy ; *Vaccination/methods ; Adult ; Colombia ; *Primary Prevention/methods ; Young Adult ; Consensus ; *Vaccines/administration & dosage ; },
abstract = {OBJETIVO: generar recomendaciones para la vacunación de la mujer, en las diferentes etapas de su vida, a fin de disminuir la posible variabilidad de su uso actual en Colombia. Materiales y métodos: el grupo desarrollador estuvo conformado por profesionales pertenecientes al área de la salud. Todos los participantes declararon por escrito sus conflictos de interés. Se formularon preguntas clínicas contestables, se hizo la graduación de los desenlaces y la pesquisa de la información se realizó en Medline/PubMed, Embase y Lilacs. La búsqueda también abarcó fuentes de literatura gris y se actualizó el 14 de mayo de 2024 sin restricciones por fecha o idioma. Se implementó la metodología GRADE (Grading of Recommendations Assessment, Development and Evaluation) para establecer la calidad de la evidencia y la fuerza de la recomendación. En virtud de las limitaciones de los estudios recuperados, y especialmente cuando se trató de limitaciones en la aplicabilidad de la evidencia, se acudió a la opinión de expertos. Se realizó consenso formal acorde con la metodología RAND/UCLA (RAND Corporation/Universidad de California en Los Ángeles). Previo a la publicación, el documento fue objeto de revisión por pares.

RESULTADOS: se desarrollaron las siguientes recomendaciones: • El grupo desarrollador sugiere que las mujeres no inmunes a las paperas, sarampión o rubeola (p. ej., IgG negativo) sean vacunadas durante el periodo preconcepcional. Calidad de la evidencia: baja ⨁⨁◯◯ • El grupo desarrollador sugiere que todas las mujeres en periodo preconcepcional se vacunen contra la varicela si no tienen inmunidad natural confirmada (p. ej., anticuerpos IgG negativo para el virus varicela zóster). Calidad de la evidencia: muy baja ⨁◯◯◯ • El grupo desarrollador sugiere que las mujeres que viven en regiones endémicas para fiebre amarilla se vacunen durante el periodo preconcepcional si no han sido previamente inmunizadas. Calidad de la evidencia: muy baja ⨁◯◯◯ • El grupo desarrollador sugiere vacunar adolescentes y adultas jóvenes con la vacuna para el virus del papiloma humano (VPH), de 3 dosis (0,2 y 6 meses) con el fin de reducir la incidencia y mortalidad por cáncer cervical. Calidad de evidencia: moderada ⨁⨁⨁◯ • El grupo desarrollador sugiere que las mujeres gestantes sean inmunizadas contra el tétano, la difteria y la tos ferina durante la gestación, con el objetivo de reducir el riesgo de infección en la madre y el neonato. Calidad de la evidencia: baja ⨁⨁◯◯ • El grupo desarrollador sugiere la vacunación contra la influenza a cualquier edad gestacional, con el objetivo de reducir el riesgo de infección en la madre y el neonato hasta los seis meses de edad. Calidad de la evidencia: muy baja ⨁◯◯◯ • El grupo desarrollador sugiere la vacunación materna frente al COVID-19 a cualquier edad gestacional, con el objetivo de reducir el riesgo de hospitalización y muerte de la madre y el neonato durante los primeros cuatro meses de vida. Calidad de la evidencia: muy baja ⨁◯◯◯ • El grupo desarrollador sugiere la vacunación contra el virus sincitial respiratorio (VSR) en mujeres gestantes, con el objetivo de reducir el riesgo de hospitalización en el neonato. Calidad de la evidencia: muy baja ⨁◯◯◯ • El grupo desarrollador sugiere que la mujer adulta mayor se vacune contra el herpes zóster, con el fin de reducir la morbilidad asociada a esta condición. Calidad de la evidencia: moderada ⨁⨁⨁◯ • El grupo desarrollador sugiere que la mujer adulta mayor se vacune contra la influenza a fin de reducir la incidencia de infección respiratoria aguda (IRA). Calidad de la evidencia: moderada ⨁⨁⨁◯ • El grupo desarrollador sugiere que la mujer adulta mayor se vacune contra el neumococo a fin de reducir la incidencia de neumonía y enfermedad neumocócica invasora. Calidad de la evidencia: baja ⨁⨁◯◯ • El grupo desarrollador sugiere que la mujer adulta mayor se vacune contra el VSR a fin de reducir la incidencia de infección respiratoria aguda e infección respiratoria del tracto inferior. Calidad de la evidencia: baja ⨁⨁◯◯ • El grupo desarrollador sugiere que la mujer adulta mayor que vive en regiones endémicas para fiebre amarilla se vacune si no ha sido previamente inmunizada. Calidad de la evidencia: muy baja ⨁◯◯◯ Conclusiones: se recomienda la vacunación como estrategia de prevención primaria a lo largo de las diferentes etapas de la vida en la mujer. Dada la calidad de la evidencia y las serias limitaciones en la aplicabilidad de algunos estudios, especialmente en mujeres gestantes, se requieren más investigaciones que evalúen la seguridad y la efectividad de esta intervención en esta etapa de la vida.},
}

Humans
Female
Pregnancy
*Vaccination/methods
Adult
Colombia
*Primary Prevention/methods
Young Adult
Consensus
*Vaccines/administration & dosage

@article {pmid41401334,
year = {2025},
author = {Gabor, M and Schlosserova, A and Korchynska, OO},
title = {Vaccination in pregnancy: a systematic review of current evidence.},
journal = {Wiadomosci lekarskie (Warsaw, Poland : 1960)},
volume = {78},
number = {10},
pages = {2142-2146},
doi = {10.36740/WLek/213601},
pmid = {41401334},
issn = {0043-5147},
mesh = {Humans ; Pregnancy ; Female ; *COVID-19/prevention & control ; *Influenza, Human/prevention & control ; *Pregnancy Complications, Infectious/prevention & control ; *Vaccination ; *Influenza Vaccines/administration & dosage ; *COVID-19 Vaccines/administration & dosage ; *Whooping Cough/prevention & control ; *Pertussis Vaccine ; },
abstract = {OBJECTIVE: Aim: To summarize current recommendations and the state of knowledge on vaccination of pregnant women against influenza, pertussis, and Covid-19, and to highlight evidence on the efficacy and safety of vaccination during pregnancy.

PATIENTS AND METHODS: Materials and Methods: A systematic literature review of studies published between 2014 and 2024 in the PubMed, Science Direct, Google Scholar, and NCBI databases was conducted. Of the total number of 31 studies found, 10 that met our required conditions were included. The inclusion criteria were peer-reviewed articles dealing with vaccination during pregnancy. Data selection and extraction were performed in accordance with PRISMA recommendations.

CONCLUSION: Conclusions: Vaccination of pregnant women appears to be a safe and effective way to protect mothers and their offspring. Emphasis should be placed on raising awareness and education in clinical practice.},
}

Humans
Pregnancy
Female
*COVID-19/prevention & control
*Influenza, Human/prevention & control
*Pregnancy Complications, Infectious/prevention & control
*Vaccination
*Influenza Vaccines/administration & dosage
*COVID-19 Vaccines/administration & dosage
*Whooping Cough/prevention & control
*Pertussis Vaccine

@article {pmid41399268,
year = {2025},
author = {Fedorchenko, Y and Zimba, O},
title = {Ethical Use of Artificial Intelligence for Processing Medical Images.},
journal = {Journal of Korean medical science},
volume = {40},
number = {48},
pages = {e341},
doi = {10.3346/jkms.2025.40.e341},
pmid = {41399268},
issn = {1598-6357},
mesh = {Humans ; *Artificial Intelligence/ethics ; *Image Processing, Computer-Assisted/ethics ; *Diagnostic Imaging/ethics ; COVID-19 ; Algorithms ; Deep Learning ; SARS-CoV-2 ; },
abstract = {Artificial intelligence (AI) tools employ prompts and algorithms to perform tasks that typically require human expertise, hypothesis formulation, and critical evaluation. AI enables rapid analysis of complex imaging data, automates segmentation and lesion detection, and supports real-time image-guided interventions. Deep learning architectures (CNNs, RNNs, U-Net, and transformer-based models) facilitate advanced image classification, reconstruction, and interpretation, achieving clinical accuracies above 90% in multiple domains, including coronavirus disease 2019, oncology, and rheumatology. Generative AI platforms (MedGAN, StyleGAN, CycleGAN, SinGAN-Seg) further support synthetic image creation and dataset augmentation, mitigating data scarcity while preserving patient privacy. However, the integration of AI in healthcare presents significant ethical challenges. Key concerns include algorithmic bias, patient privacy, transparency, accountability, and equitable access. Biases-such as annotation, automation, confirmation, demographic, and feedback-loop bias-can compromise diagnostic reliability and patient outcomes. Ethical deployment requires rigorous data governance, informed consent, anonymization, standardized validation frameworks, human oversight, and regulatory compliance. Maintaining interpretability and transparency of AI outputs is essential for clinical decision-making, while professional training and AI literacy are critical to mitigate overreliance and ensure patient safety.},
}

Humans
*Artificial Intelligence/ethics
*Image Processing, Computer-Assisted/ethics
*Diagnostic Imaging/ethics
COVID-19
Algorithms
Deep Learning
SARS-CoV-2

@article {pmid41398580,
year = {2025},
author = {Manarte, R and Henriques, MR},
title = {From exceptionalism to universal testing: an historical review of HIV testing in Portugal.},
journal = {BMC public health},
volume = {25},
number = {1},
pages = {4251},
pmid = {41398580},
issn = {1471-2458},
mesh = {Portugal/epidemiology ; Humans ; *HIV Infections/diagnosis ; *HIV Testing/history ; *Health Policy ; History, 20th Century ; History, 21st Century ; *Mass Screening/history ; *Universal Health Care ; },
abstract = {INTRODUCTION: Portugal has made significant progress over the last 40 years in the response against the Human Immunodeficiency Virus (HIV) infection and the Acquired Immunodeficiency Syndrome (AIDS). However, as of 2021, it remained one of the three Western European countries with the highest rates of new HIV infections and AIDS cases. Initially shaped by HIV exceptionalism, Portugal began transitioning to a universal testing strategy in 2011. This study provides a historical and policy review of the evolution of HIV testing in Portugal, focusing on alignment with international guidelines and national implementation outcomes.

METHODS: We conducted a narrative policy review covering the period from 1998 to 2024. Our analysis drew on scientific literature, national health plans, surveillance reports, and international guidelines. Documents were selected through structured searches in multiple academic databases and government repositories using relevant Portuguese and English search terms. Thematically coded findings were mapped chronologically and assessed against evolving WHO and CDC recommendations.

RESULTS: Portugal gradually moved from a targeted testing approach to a more comprehensive, universal strategy. Key policy shifts occurred in 2011 and 2017, accompanied by an expansion of testing modalities, including self-testing and community-based testing. Despite these developments, implementation has been uneven. The lack of standardized protocols, limited integration into primary healthcare, and regional disparities tied to a contract-based health system have contributed to inconsistent service delivery. Additionally, testing uptake among older adults, migrants, and other key populations remains suboptimal. The COVID-19 pandemic temporarily disrupted testing services but also accelerated the use of self-testing strategies.

DISCUSSION: Portugal's experience illustrates the challenges of operationalizing universal HIV testing within a hybrid public-private healthcare system. Although policies increasingly reflect international best practices, structural barriers continue to hinder equitable implementation.

CONCLUSION: To close existing testing gaps, Portugal must strengthen implementation by standardizing procedures, improve disaggregated data collection in monitoring systems, and ensure greater integration of HIV testing in primary healthcare. Enhanced outreach to underserved populations will be critical to achieving national and international HIV prevention targets. This paper offers a historical and policy perspective to inform more equitable and effective national testing strategies.},
}

Portugal/epidemiology
Humans
*HIV Infections/diagnosis
*HIV Testing/history
*Health Policy
History, 20th Century
History, 21st Century
*Mass Screening/history
*Universal Health Care

@article {pmid41398527,
year = {2025},
author = {Maleki, F and Hosseinpour, M and Pashaei, MR and Aghdam, ME and Bahardoust, M and Delpisheh, A},
title = {Body mass index in children with newly diagnosed celiac disease: A systematic review and meta-analysis.},
journal = {European journal of pediatrics},
volume = {185},
number = {1},
pages = {18},
pmid = {41398527},
issn = {1432-1076},
mesh = {Humans ; *Celiac Disease/diagnosis/complications/diet therapy/epidemiology ; *Body Mass Index ; Child ; *Thinness/epidemiology ; Prevalence ; Diet, Gluten-Free ; *Pediatric Obesity/epidemiology ; Child, Preschool ; },
abstract = {UNLABELLED: Clinical manifestations of celiac disease (CeD) in children are often associated with malabsorption, malnutrition, and underweight. Recent evidence suggests an increased prevalence in normal-weight and obese children. Under-recognition of patients with normal or high BMI can lead to delayed diagnosis and serious complications. The present study aimed to determine the BMI status of children with CeD at diagnosis and before gluten-free diet (GFD). A systematic review and meta-analysis was conducted following the PRISMA and MOOSE guidelines and after PROSPERO registration (CRD42023390243). The information sources, including PubMed, Scopus, and Web of Science, were systematically searched through 30 September 2025 to identify relevant articles. The study's eligibility criteria included observational studies, such as retrospective, cross-sectional, and prospective designs, with participants whose CeD diagnosis was confirmed by a gastroenterologist and who reported BMI data at the time of diagnosis. Heterogeneity among studies was assessed using the I[2] statistic. Funnel plots and Egger's test were also used to examine publication bias. The risk of bias of studies was assessed using the Newcastle-Ottawa (NOS) scale. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework was used to determine the certainty of the evidence. Overall, 32 studies including 14,169 children with CeD were investigated. The pooled prevalence of underweight and overweight/obesity at diagnosis was 15.3% (10.8-20.4%) and 10.5% (5.7-16.4%), respectively. Subgroup analysis by WHO region revealed a marked heterogeneity (I[2] > 90%), with the highest prevalence of underweight observed in the Eastern Mediterranean Region (EMRO) (31.9%). On the other hand, the highest prevalence of overweight/obesity was observed in the European Region (EURO) (12.0%) and the Western Pacific Region (WPRO) (21.4%). A key finding was a significant difference across World Bank income groups; underweight prevalence was nearly four times higher in low- and middle-income countries (LMICs), 35.48 (24.29, 47.51), compared with high-income countries, 9.58 (6.88, 12.63). The certainty of the evidence for all pooled prevalence estimates was rated as very low due to serious inconsistency and imprecision.

CONCLUSIONS:  The prevalence of normal weight and overweight/obesity in children with celiac disease at diagnosis was higher than that of underweight, mainly in high-income countries. This finding challenges the traditional belief about the CeD and emphasizes its diagnosis in children with suspicious symptoms, regardless of their BMI status. This approach will lead to earlier diagnosis, improving clinical outcomes and quality of life for patients in the long term.

WHAT IS KNOWN: • The clinical presentation of celiac disease is evolving, and its association with underweight is inconsistent. • The structural effects of COVID-19 on the developing brain remain poorly understood due to limited pediatric imaging studies.

WHAT IS NEW: • This is the first meta-analysis focused exclusively on children, revealing that the majority (70.2%) present with a normal BMI at diagnosis. • The clinical inconsistency in BMI presentation is strongly linked to income levels; underweight prevalence is nearly four times higher in LMICs (35.5%) than in high-income countries (9.6%).},
}

Humans
*Celiac Disease/diagnosis/complications/diet therapy/epidemiology
*Body Mass Index
Child
*Thinness/epidemiology
Prevalence
Diet, Gluten-Free
*Pediatric Obesity/epidemiology
Child, Preschool

@article {pmid41397515,
year = {2025},
author = {Chen, P and Prosser, M and Phillips, B and Ellison CEng, P and Rangan, A},
title = {Accuracy and Reliability of Remote Shoulder Motion Capturing Methods: A Systematic Review and Meta-Analysis.},
journal = {Journal of shoulder and elbow surgery},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.jse.2025.11.007},
pmid = {41397515},
issn = {1532-6500},
abstract = {BACKGROUND: The COVID-19 pandemic accelerated the demand for remote assessment tools in rehabilitation, especially the need for accurate and reliable technologies to measure shoulder range of motion (ROM) outside of clinical environments. Emerging tools such as smartphone apps, wearable sensors, and markerless motion capture systems are increasingly being adopted, yet their accuracy and reliability compared to reference standards remains unclear.

OBJECTIVE: To systematically evaluate the accuracy and reliability of existing remote shoulder ROM measurement technologies, quantify measurement bias, and assess their agreement with reference standards.

METHODS: A systematic review and meta-analysis was conducted on 26 studies evaluating remote ROM measurement tools. Pooled mean bias (in degrees) was calculated as the primary effect size for agreement, with reliability assessed using intraclass correlation coefficients (ICCs). Subgroup analyses were performed by motion type, technology category, population health status, and data acquisition method. Risk of bias was assessed using the QUADAS-2 tool.

RESULTS: Remote measurement methods showed a small but consistent overestimation of ROM compared to reference standards (pooled mean bias = 2.63°, 95% CI: 1.52°, 3.74°), particularly in flexion, internal rotation, and external rotation. No significant bias was observed in abduction or extension. Both IMU and non-IMU technologies demonstrated comparable levels of overestimation. Pathological populations exhibited greater variability (bias = 4.33° vs. 2.37° in healthy subjects). Self-measurements showed lower and non-significant bias compared to assessor-guided methods. Reliability was generally high, especially for test-retest assessments (ICCs > 0.90), though more variable in inter-rater and pathological settings.

CONCLUSION: Remote shoulder ROM measurement technologies tend to slightly overestimate joint angles but remain within clinically acceptable limits. These tools are reliable for tracking ROM trends and suitable for remote monitoring in clinical and research settings. However, increased variability in pathological populations warrants caution. Broader validation in diverse patient cohorts is needed to strengthen clinical implementation.},
}

@article {pmid41397310,
year = {2025},
author = {Cho, AH and Cho, SY and Kim, S and Lee, S},
title = {Targeting emerging viruses with phage display-driven engineered antibodies: Bridging molecular design and clinical application.},
journal = {Molecular aspects of medicine},
volume = {107},
number = {},
pages = {101441},
doi = {10.1016/j.mam.2025.101441},
pmid = {41397310},
issn = {1872-9452},
abstract = {Phage display (PD) is a powerful platform that accelerates the discovery and engineering of therapeutic antibodies across diverse diseases, including emerging and re-emerging viral infections. The COVID-19 pandemic highlighted the urgency for rapid and adaptable antibody development against highly mutable pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PD technology enables the rapid and high-throughput identification, optimization, and efficient reformatting of virus-neutralizing antibodies, yielding fully PD-derived antibodies and reformatted derivatives from PD fragments without requiring convalescent samples or animal immunization. This approach supports a proactive and scalable strategy for pandemic preparedness. This review provides a comprehensive overview of PD-derived therapeutic antibodies targeting infectious diseases, focusing on approved agents and candidates in clinical or preclinical development for SARS-CoV-2. We highlight recent case studies, including our own, showing the successful application of PD in generating potent neutralizing and multispecific antibody formats. These offer functional advantages such as enhanced breadth and affinity while also serving as versatile molecular tools for elucidating viral pathogenesis and immune evasion mechanisms. Despite PD's technological strengths, the clinical advancement of PD-derived candidates has been influenced by external circumstances associated with the evolving pandemic landscape, highlighting the need to strategically leverage PD's strengths to accelerate translational outcomes in future outbreaks. This review offers a well-rounded viewpoint on PD, outlining its applications, addressing its challenges, and incorporating emerging innovations into PD workflows. These advances position PD-derived candidates as a strategic, versatile, and rapid-response platform that bridges molecular insights with clinical translation, offering a robust framework for addressing current and future infectious disease challenges.},
}

@article {pmid33909785,
year = {2021},
author = {Beck, ALS and Barberato, SH and Almeida, ALC and Grau, CRPC and Lopes, MMU and Lima, RSL and Cerci, RJ and Albricker, ACL and Barros, FS and Oliveira, AJ and Lira Filho, EB and Miglioranza, MH and Vieira, MLC and Pena, JLB and Strabelli, TMV and Bihan, DCSL and Tsutsui, JM and Rochitte, CE},
title = {Position Statement on Indications and the Safe Reintroduction of Cardiovascular Imaging Methods in the COVID-19 Scenario - 2021.},
journal = {Arquivos brasileiros de cardiologia},
volume = {116},
number = {3},
pages = {659-678},
pmid = {33909785},
issn = {1678-4170},
mesh = {Humans ; *Cardiovascular System ; *COVID-19 ; SARS-CoV-2 ; Societies, Medical ; },
}

Humans
*Cardiovascular System
*COVID-19
SARS-CoV-2
Societies, Medical

@article {pmid32472377,
year = {2020},
author = {Ganau, M and Netuka, D and Broekman, M and Zoia, C and Tsianaka, E and Schwake, M and Balak, N and Sekhar, A and Ridwan, S and Clusmann, H and , },
title = {Neurosurgeons and the fight with COVID-19: a position statement from the EANS Individual Membership Committee.},
journal = {Acta neurochirurgica},
volume = {162},
number = {8},
pages = {1777-1782},
pmid = {32472377},
issn = {0942-0940},
mesh = {Humans ; *Access to Information ; Betacoronavirus ; *Communication ; *Coronavirus Infections/epidemiology ; COVID-19 ; Europe/epidemiology ; Neurosurgeons ; Neurosurgery ; Pandemics ; *Personal Protective Equipment ; *Pneumonia, Viral/epidemiology ; SARS-CoV-2 ; Societies, Medical ; *Stress, Psychological ; },
}

Humans
*Access to Information
Betacoronavirus
*Communication
*Coronavirus Infections/epidemiology
COVID-19
Europe/epidemiology
Neurosurgeons
Neurosurgery
Pandemics
*Personal Protective Equipment
*Pneumonia, Viral/epidemiology
SARS-CoV-2
Societies, Medical
*Stress, Psychological

@article {pmid32407899,
year = {2020},
author = {Lavoué, V and Akladios, C and Gladieff, L and Classe, JM and Lécuru, F and Collinet, P},
title = {Onco-gynecologic surgery in the COVID-19 era: Risks and precautions-A position paper from FRANCOGYN, SCGP, SFCO, and SFOG.},
journal = {Journal of gynecology obstetrics and human reproduction},
volume = {49},
number = {7},
pages = {101787},
pmid = {32407899},
issn = {2468-7847},
mesh = {Female ; Humans ; Anesthesiologists ; Antineoplastic Agents/therapeutic use ; *Betacoronavirus ; Consensus ; *Coronavirus Infections/epidemiology/prevention & control/transmission ; COVID-19 ; France/epidemiology ; *Genital Neoplasms, Female/diagnosis/therapy ; *Gynecologic Surgical Procedures ; *Occupational Diseases/prevention & control ; *Pandemics/prevention & control ; Personal Protective Equipment ; *Pneumonia, Viral/epidemiology/prevention & control/transmission ; Preoperative Care/methods ; SARS-CoV-2 ; *Societies, Medical ; Surgeons ; Telemedicine ; Withholding Treatment ; },
}

Female
Humans
Anesthesiologists
Antineoplastic Agents/therapeutic use
*Betacoronavirus
Consensus
*Coronavirus Infections/epidemiology/prevention & control/transmission
COVID-19
France/epidemiology
*Genital Neoplasms, Female/diagnosis/therapy
*Gynecologic Surgical Procedures
*Occupational Diseases/prevention & control
*Pandemics/prevention & control
Personal Protective Equipment
*Pneumonia, Viral/epidemiology/prevention & control/transmission
Preoperative Care/methods
SARS-CoV-2
*Societies, Medical
Surgeons
Telemedicine
Withholding Treatment

@article {pmid41394882,
year = {2025},
author = {Padilla-Blanco, M and García-García, T and Grigas, J and López-Ayllón, BD and Garrido, JJ and Oliva, MA and Montoya, M},
title = {Hidden players of COVID-19: the evolving roles of SARS-CoV-2 accessory proteins.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1726698},
pmid = {41394882},
issn = {1664-3224},
mesh = {Humans ; *SARS-CoV-2/immunology/genetics ; *COVID-19/immunology/virology ; Host-Pathogen Interactions/immunology ; Interferon Type I/immunology/metabolism ; Animals ; *Viral Regulatory and Accessory Proteins/immunology/genetics/metabolism ; Viral Proteins/immunology ; },
abstract = {SARS-CoV-2 accessory proteins (APs), particularly ORF3a and ORF9b, have emerged as key modulators of host-pathogen interaction and potential contributors to long COVID. Of the 13 predicted APs, only nine are expressed during infection - termed Infection-related APs - while the remaining are classified as Putative APs. Despite this distinction, extensive gene overlap among APs underscores the remarkable adaptability of SARS-CoV-2 viral genome. This review delves into the diverse roles of the original Wuhan APs and their Omicron counterparts in shaping host immunity, with an emphasis on their ability to suppress type I interferon (IFN-I) signalling, modulate cellular metabolism, and trigger inflammatory/apoptotic pathways. By integrating immunopathological insights with evolutionary dynamics and structural perspectives, this review provides a comprehensive understanding of the mechanism underlying Omicron's reduced pathogenicity and highlights promising, yet unexplored, therapeutic targets within the SARS-CoV-2 accessory proteome.},
}

Humans
*SARS-CoV-2/immunology/genetics
*COVID-19/immunology/virology
Host-Pathogen Interactions/immunology
Interferon Type I/immunology/metabolism
Animals
*Viral Regulatory and Accessory Proteins/immunology/genetics/metabolism
Viral Proteins/immunology

@article {pmid41394849,
year = {2025},
author = {Gabig-Cimińska, M},
title = {Dysregulated TFEB-autophagy-lysosome pathway links acute COVID-19 immunopathology to Long COVID sequelae.},
journal = {Frontiers in immunology},
volume = {16},
number = {},
pages = {1708364},
pmid = {41394849},
issn = {1664-3224},
mesh = {Humans ; *COVID-19/immunology/pathology/complications ; *Lysosomes/immunology/metabolism ; *Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism/immunology ; *Autophagy/immunology ; *SARS-CoV-2/immunology ; Animals ; Signal Transduction/immunology ; Immunity, Innate ; },
abstract = {SARS-CoV-2 disrupts cellular homeostasis, including the autophagy-lysosome pathway (ALP), a critical component of innate immunity and viral clearance. By subverting autophagy, SARS-CoV-2 proteins such as ORF3a, ORF7a, and NSP6 inhibit autophagosome-lysosome (APG-L) fusion, generating "incomplete autophagy" that permits viral persistence and drives hyperinflammation. Transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy, has emerged as a central player in the host response to coronavirus infection. TFEB orchestrates the expression of genes required for lysosomal function and autophagic flux while also shaping immune processes, including cytokine production, interferon-stimulated gene expression, and inflammasome clearance. This mini review synthesizes current knowledge on the TFEB-ALP axis in COVID-19 pathogenesis, highlighting its influence on acute immunopathology and its potential contribution to post-acute sequelae (Long COVID). Restoring TFEB activity and autophagic flux may counteract SARS-CoV-2 evasion strategies and restrain aberrant inflammatory responses. Harnessing the TFEB-autophagy pathway as a host-directed therapeutic strategy could help rebalance immune homeostasis, limit tissue damage during acute infection, and mitigate persistent inflammatory sequelae in Long COVID.},
}

Humans
*COVID-19/immunology/pathology/complications
*Lysosomes/immunology/metabolism
*Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism/immunology
*Autophagy/immunology
*SARS-CoV-2/immunology
Animals
Signal Transduction/immunology
Immunity, Innate

@article {pmid41392909,
year = {2025},
author = {Pandey, V and Sen, D and Rathee, S and Soni, S and Mishra, S and Jain, SK and Patil, UK},
title = {Unlocking Toll-Like Receptors: Targeting Therapeutics for Respiratory Tract Infections and Inflammatory Disorders.},
journal = {Recent advances in inflammation & allergy drug discovery},
volume = {19},
number = {3},
pages = {303-315},
doi = {10.2174/0127722708329138240926073013},
pmid = {41392909},
issn = {2772-2716},
mesh = {Humans ; *Toll-Like Receptors/immunology/metabolism/antagonists & inhibitors ; COVID-19/immunology ; *Respiratory Tract Infections/drug therapy/immunology ; *Inflammation/drug therapy/immunology ; *COVID-19 Drug Treatment ; Animals ; SARS-CoV-2 ; Signal Transduction/drug effects ; Immunity, Innate/drug effects ; },
abstract = {The Toll-like Receptors (TLRs) family has significantly enhanced the understanding of innate immune responses by identifying and responding to various microbes or host-derived organisms. TLRs contribute to these responses by increasing the levels of cytokines, interleukins, and other inflammatory mediators through multiple pathways. Located both intracellularly and on the surface of various cells and tissues, including vascular smooth muscles (VSMs) and myocardium cells, TLRs play distinct roles in innate immune activation, such as recognizing pathogen-associated molecular patterns (PAMPs) and activating downstream signaling pathways. In the context of COVID-19, TLRs are critically involved in the pathophysiology by mediating excessive inflammatory responses that exacerbate disease severity, influencing both the acute phase and long-term outcomes. It has been observed that inflammatory diseases such as atherosclerosis, viral myocarditis, and other comorbidities associated with the spread of COVID-19 have increased, although the exact mechanisms remain not fully understood. Nonetheless, there is evidence of TLR-mediated increased pro-inflammatory signaling by different mechanisms in these diseases. This review explains the role of TLRs in various inflammatory diseases related to COVID-19, including viral myocarditis, acute lung infections, and atherosclerosis. Furthermore, the review discusses various herbal drugs, such as Platycodon grandiflorum, Acanthopanax senticosus, Scutellaria baicalensis Georgi, and Engelhardia roxburghiana, and their mechanisms of action on TLRs, including NF-κB, MyD88-dependent, MyD88-independent pathways, and Plasmacytoid DCs. Enhanced clarity on TLRs' specific contributions to COVID-19 pathophysiology and stronger evidence supporting herbal interventions targeting TLRs could improve the impact and applicability of these findings in clinical settings.},
}

Humans
*Toll-Like Receptors/immunology/metabolism/antagonists & inhibitors
COVID-19/immunology
*Respiratory Tract Infections/drug therapy/immunology
*Inflammation/drug therapy/immunology
*COVID-19 Drug Treatment
Animals
SARS-CoV-2
Signal Transduction/drug effects
Immunity, Innate/drug effects

@article {pmid41392882,
year = {2025},
author = {de Bruin, O and Maisonneuve, E and Hurley, E and Nordeng, HME and Bérard, A and Sheehy, O and Kaul, P and Shinde, MU and Cosgrove, A and Lyons, JG and Messenger-Jones, E and Kempner, ME and Toh, S and Hua, W and Hernández-Muñoz, JJ and Sahin, L and Cesta, CE and Hägg, D and Gini, R and Paoletti, O and Poblador-Plou, B and Jordan, S and Rodríguez-Bernal, CL and Sánchez-Sáez, F and Lassalle, R and Bernard, MA and Ahmadizar, F and Favre, G and Panchaud, A and Bloemenkamp, KWM and Plueschke, K and de Vries, C and Siiskonen, SJ and Sturkenboom, MCJM and , },
title = {Adverse outcomes among pregnant women with COVID-19 according to hospitalization status: A prospective individual participant data meta-analysis in Europe and North America.},
journal = {International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics},
volume = {},
number = {},
pages = {},
doi = {10.1002/ijgo.70694},
pmid = {41392882},
issn = {1879-3479},
support = {//European Medicines Agency/ ; /CAPMC/CIHR/Canada ; //Canada Foundation for Innovation/ ; /FD/FDA HHS/United States ; },
abstract = {BACKGROUND: Understanding the varied impact of COVID-19 severity on pregnancy outcomes is crucial for informed clinical management and targeted interventions.

OBJECTIVE: To evaluate the impact of COVID-19 on pregnancy outcomes, distinguishing between pregnant women managed in primary care and those requiring hospitalization.

SEARCH STRATEGY: Regulatory authorities actively promoted global cooperation on COVID-19's impact during pregnancy. Data were obtained through these regulatory bodies and direct researcher communication rather than through systematic searches.

SELECTION CRITERIA: Data sources required secondary population-based data to identify pregnancies with COVID-19, along with hospitalization, diagnostic and medication codes. Eligibility for the meta-analysis was determined through protocol evaluation and researcher consultations.

DATA COLLECTION AND ANALYSIS: PRISMA-IPD and Cochrane guidelines for prospective meta-analysis were followed. Protocols and definitions were standardized across sources, and a common R script was developed. Initially, crude and adjusted relative risks (aRR) with 95% confidence intervals (CI) were calculated to assess adverse outcomes in pregnant women with and without COVID-19 in each data source. Estimates were stratified by trimester at infection and hospitalization status. Subsequently, data were pooled using a random-effects meta-analysis.

MAIN RESULTS: Data from 10 sources across seven countries contributed to the meta-analysis, including 86 210 pregnant women diagnosed with COVID-19, of whom 4.4% were hospitalized. Non-hospitalized pregnant women with COVID-19 had no increased risks of adverse outcomes compared to pregnant women without COVID-19. However, hospitalized women with COVID-19 in each trimester had higher risks of cesarean section, preterm birth, and LBW compared to pregnant women without COVID-19. Hospitalization due to COVID-19 in the third trimester was associated with increased risk of stillbirth (aRR 5.90, 95% CI: 2.22-15.71, I[2] = 0%). First-trimester hospitalizations due to COVID-19 did not show heightened risks of GDM (aRR 2.08, 95% CI: 0.93-4.64, I[2] = 65%), pre-eclampsia (aRR 1.79, 95% CI: 0.48-6.66, I[2] = 71%), or major congenital anomalies (aRR 1.30, 95% CI: 0.55-3.06, I[2] = 0%).

CONCLUSIONS AND RELEVANCE: COVID-19 requiring hospitalization is associated with adverse pregnancy outcomes, emphasizing the need to prevent severe illness during pregnancy. This study also highlights the importance of international collaboration for gathering pregnancy data and shows that building global research networks is essential for responding to future health crises.},
}

@article {pmid41392436,
year = {2025},
author = {Celano, R and Urso, F and Bartoli, A and Meschia, A and Masseroli, MM and Cirigliano, F and Colaneri, M and Foschi, A and Gori, A and Cogliati, C and Calloni, M and Taino, A and Scoppettuolo, G and Pittiruti, M and Gidaro, A},
title = {COVID-19 and vascular access: Evidence and lessons for improving the standard of care, a scoping review.},
journal = {The journal of vascular access},
volume = {},
number = {},
pages = {11297298251398421},
doi = {10.1177/11297298251398421},
pmid = {41392436},
issn = {1724-6032},
abstract = {The Coronavirus Disease 2019 (COVID-19) pandemic has significantly impacted intravenous therapy practices, particularly in critically ill patients. Vascular access strategies were adapted to evolving clinical needs, infection control priorities, and resource limitations, with a focus on safety, efficacy, and technological advancements. This scoping review aimed to explore how the COVID-19 pandemic affected vascular access practices and catheter-related complications, with the objective of mapping innovations, identifying emerging trends, and summarizing preventive and therapeutic strategies. The review followed PRISMA-ScR guidelines and was registered in PROSPERO (CRD420251027530). A systematic search was conducted in PubMed[®], EMBASE[®], EBSCO-CINAHL[®], and CENTRAL for English-language studies published between January 2020 and May 2025 addressing catheter-related complications in COVID-19 patients, including catheter-related bloodstream infections (CRBSI), central line-associated bloodstream infections (CLABSI), catheter-related thrombosis (CRT), and accidental catheter removal. Among 521 screened articles, 58 met the inclusion criteria. Most studies reported higher rates of CRBSI, CLABSI, CRT, and accidental removal in COVID-19 patients, especially in critical care settings. Arterial catheters were also associated with elevated risks of thrombosis and infection during the pandemic. Mid-thigh femoral access sites emerged as practical alternatives to reduce central line use and healthcare personnel exposure. Technological advances, including power-injectable catheters, ultrasound-guided insertion, intracavitary ECG for tip confirmation, and securement tools such as cyanoacrylate glue and subcutaneous anchor systems, improved safety and reduced mechanical and infectious complications. Chlorhexidine-based antisepsis, antimicrobial-impregnated devices, and disinfectant caps effectively decreased CRBSI and CLABSI rates. In older, comorbid patients-now representing the majority of COVID-19 hospitalizations-nutritional and anticoagulant therapy must be carefully balanced to minimize bleeding and thrombotic risks. In conclusion, the pandemic catalyzed significant innovation and adaptation in vascular access practices. Integrating portable technologies, infection prevention strategies, and alternative access routes has enhanced patient care and established new standards for managing intravenous therapy in high-risk, resource-constrained settings.},
}

@article {pmid41391467,
year = {2025},
author = {Rutter, H and Wabnitz, K and Nambiar, D and Garde, A and Benton, TG and Heymann, DL and Yates, R and Friel, S and Hollands, GJ and Cai, W and Chater, N and Bloom, DE and Guinto, RR and El Omrani, O and Wilsdon, J and Amuasi, JH and Butler, C and Tlou, S and Marteau, TM},
title = {The Lancet Commission on improving population health post-COVID-19.},
journal = {Lancet (London, England)},
volume = {},
number = {},
pages = {},
doi = {10.1016/S0140-6736(25)02061-6},
pmid = {41391467},
issn = {1474-547X},
}

@article {pmid41390653,
year = {2025},
author = {Waqqas, HM and Pan, J and Xia, N and Chen, W},
title = {mRNA based vaccines and therapeutics for parasitic infections: a comprehensive review.},
journal = {Journal of nanobiotechnology},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12951-025-03787-z},
pmid = {41390653},
issn = {1477-3155},
support = {SKLRD-OP-202409//Open Project of the State Key Laboratory of Respiratory Disease/ ; },
abstract = {The success of mRNA vaccines during the COVID-19 pandemic has revealed a revolutionary platform for addressing neglected parasite zoonosis, which represent a continual and significant threat to world health, especially in resource-constrained settings. The current review consolidates recent progress in the development of mRNA-based treatments, vaccines, and diagnostic ways for these pathogens. We elucidate how customized delivery platforms, particularly lipid nanoparticles, augment the stability and immunogenicity of parasite-derived mRNA cargo by safeguarding it from degradation and promoting uptake by antigen-presenting cells. Our findings suggest that mRNA technology provides a particularly adaptable strategy to targeting complicated parasite life cycles and efficiently modulating host immune responses. However, important challenges, such as cold-chain logistics, scalability, clinical trial design for diverse populations, and managing public opinion, must be solved beforehand. Future initiatives must priorities the creation of thermostable formulations and effective community participation strategies. Finally, this review emphasizes that mRNA-based interventions represent a promising, albeit challenging, frontier in the fight against parasitic diseases, urging a collaborative cross-disciplinary effort to translate this potential into tangible health breakthroughs for the world's most vulnerable populations.},
}

@article {pmid41297153,
year = {2025},
author = {Kattner, AA},
title = {Sticks and stones - mending bones.},
journal = {Biomedical journal},
volume = {48},
number = {6},
pages = {100931},
pmid = {41297153},
issn = {2320-2890},
mesh = {Humans ; *COVID-19/prevention & control ; *Bone Regeneration ; COVID-19 Vaccines ; SARS-CoV-2 ; },
abstract = {A novel biomaterial demonstrates enhanced bone regeneration in critical defects, offering potential improvements in orthopedic repair. In immunology, a second booster dose of mRNA COVID-19 vaccine is shown to elicit robust responses in older adults in Taiwan. Hepatology research explores new therapeutic strategies for managing hepatitis B in kidney transplant recipients. Biomarker discovery advances with a new assay enabling the use of miRNAs for non-invasive diagnosis and staging of metabolic dysfunction-associated steatotic liver disease (MASLD). Finally, an optimized elastase assay improves FISH-based detection of ALK gene rearrangements, enhancing diagnostic accuracy in non-small cell lung cancer (NSCLC).},
}

Humans
*COVID-19/prevention & control
*Bone Regeneration
COVID-19 Vaccines
SARS-CoV-2

@article {pmid40608563,
year = {2026},
author = {Bernstein, WK and Pearl, RG and Huang, J and Mayrsohn, BG and Mery, MW and Banoub, M and Pease, S and Ayad, S and Saffary, R and Olszewski, RF and Aronson, S and Vetter, TR},
title = {Enhancing Anesthetic Preoptimization: Promising Opportunities for Innovation in Economically Diverse Regions.},
journal = {Anesthesia and analgesia},
volume = {142},
number = {1},
pages = {76-84},
pmid = {40608563},
issn = {1526-7598},
mesh = {Humans ; *COVID-19/economics/epidemiology ; *Perioperative Care/economics/methods ; *Anesthesia/economics/methods ; *Preoperative Care/economics/methods/trends ; Anesthesiologists/economics ; },
abstract = {The escalating costs of perioperative care are unsustainable, necessitating the identification of high-impact investment opportunities to enhance both quality and cost-effectiveness of perioperative processes. In both rural and urban areas with less access to health care resources, a sustainable health care system must focus on delivering value-based care and prioritizing population health, promoting efficiency, preventing complications, and optimizing outcomes. Given the shortage of primary care physicians, and the lessons learned from the COVID-19 pandemic, which emphasized the importance of a systems-based approach, as well as the evolving roles in the perioperative surgical home and ERAS pathways, anesthesiologists are in a prime position to contribute to these essential value-based objectives. They can achieve this by playing a more active role in the preoperative evaluation and optimization of patients.This paper presents a comprehensive review of pertinent perioperative medical conditions (obstructive sleep apnea, hypertension, anemia, food insecurity and nutrition, diabetes, cognitive and brain health) that can be optimized before surgery. It highlights the latest research and innovations in preoperative management that can significantly alter intraoperative anesthetic management of these conditions leading to reduced morbidity and mortality among surgical patients. Furthermore, this paper highlights existing gaps in preoperative management, particularly in the optimization of comorbid medical conditions.},
}

Humans
*COVID-19/economics/epidemiology
*Perioperative Care/economics/methods
*Anesthesia/economics/methods
*Preoperative Care/economics/methods/trends
Anesthesiologists/economics

@article {pmid41387929,
year = {2025},
author = {Kanno, H and Liu, Z and Sato, R and Endo, H and Niizuma, K and Goda, K},
title = {Single-pixel imaging flow cytometry for biomedical research.},
journal = {Inflammation and regeneration},
volume = {45},
number = {1},
pages = {36},
pmid = {41387929},
issn = {1880-9693},
abstract = {High-throughput single-cell analysis and screening have become essential tools in life science research. Imaging flow cytometry, in particular, enables large-scale image-based profiling of heterogeneous cell populations, allowing statistical analysis of cellular morphology, subcellular features, and functional responses. However, its analytical capability is often limited by the use of conventional two-dimensional (2D) image sensors. In this review, we highlight recent advances in single-pixel imaging flow cytometry, which replaces 2D image sensors with single-pixel photodetectors. This approach offers advantages in sensitivity, flexibility, and speed in imaging system design and has been implemented in various optical configurations to achieve high-throughput single-cell imaging. We first introduce its key techniques, then outline representative biomedical applications, including cancer and COVID-19 research, and finally discuss current limitations and prospects for future developments. Single-pixel imaging flow cytometry is expected to serve as a versatile platform supporting both basic and translational studies in diverse biomedical applications.},
}

@article {pmid41366793,
year = {2025},
author = {Chen, H and Zhang, J and Huang, J and Wu, Z and Tang, L and Tian, Y and Gao, S and Huang, S and Cao, J and Chen, J and Li, Y},
title = {Convergence of mRNA technology and chimeric antigen receptor therapy: targeted technology optimizing targeted therapy.},
journal = {Journal of translational medicine},
volume = {23},
number = {1},
pages = {1393},
pmid = {41366793},
issn = {1479-5876},
abstract = {Engineering cells to express chimeric antigen receptors (CARs) represents a novel approach in cancer immunotherapy, demonstrating remarkable efficacy in the treatment of hematologic malignancies while also encountering numerous challenges. Against the backdrop of the widespread application of COVID-19 mRNA vaccines, the integration of mRNA technology to produce CAR cells and enhance CAR therapies marks the cutting edge of cancer treatment innovation, offering potential solutions to the challenges faced by traditional CAR therapies. This convergence offers distinct advantages. It enables the generation of CAR cells both in vitro and in vivo without transgene integration, thereby achieving transient expression that reduces the risk of various side effects. Meanwhile, this approach entails lower production costs. This method may therefore serve as a novel and promising alternative to existing therapies in the future. In this article, we review the latest advancements and clinical applications of mRNA-based CAR therapies, which utilize mRNA technology to generate CAR-T cells. Additionally, we explore the diverse therapies enabled by mRNA technology, such as gene editing and vaccines, and their combination with CAR therapies. By analyzing their challenges and prospects, we aim to provide new insights into comprehensively improving the therapeutic efficacy of CAR therapies and expanding their clinical application.},
}